Differentiation Of Vessel Wall Cells  From Umbilical Cord Blood Mesenchymal Cells  For Vascular Tissue Engineering by Omay, Pınar Hüner
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
İSTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
Ph.D. THESIS 
MARCH 2016 
 
DIFFERENTIATION OF VESSEL WALL CELLS  
FROM UMBILICAL CORD BLOOD MESENCHYMAL CELLS  
FOR VASCULAR TISSUE ENGINEERING 
 
 
 
 
Pınar HÜNER OMAY 
Molecular Biology-Genetics and Biotechnology Department 
 
Molecular Biology-Genetics and Biotechnology Graduate Program 
 
 
  
   
MARCH 2016 
İSTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
DIFFERENTIATION OF VESSEL WALL CELLS  
FROM UMBILICAL CORD BLOOD MESENCHYMAL CELLS  
FOR VASCULAR TISSUE ENGINEERING 
 
Ph.D. THESIS 
Pınar HÜNER OMAY 
 (521062210) 
Molecular Biology-Genetics and Biotechnology Department 
 
Molecular Biology-Genetics and Biotechnology Program 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Thesis Advisor: Prof. Dr. Hakan BERMEK 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
MART 2016 
İSTANBUL TEKNİK ÜNİVERSİTESİ  FEN BİLİMLERİ ENSTİTÜSÜ 
DAMAR DOKU MÜHENDİSLİĞİ AMACIYLA  
KORDON KANI MEZENKİMAL HÜCRELERİNDEN  
DAMAR DUVARI ENDOTEL HÜCRE FARKLILAŞMASI 
DOKTORA TEZİ 
Pınar HÜNER OMAY 
(521062210) 
Moleküler Biyoloji-Genetik ve Biyoteknoloji Anabilim Dalı 
 
Moleküler Biyoloji-Genetik ve Biyoteknoloji Lisansüstü Programı 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Tez Danışmanı: Prof. Dr. Hakan BERMEK 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Thesis Advisor :  Prof. Dr. Hakan BERMEK   .............................. 
 İstanbul Technical University  
Jury Members :  Prof. Dr. Levent TRABZON  ............................. 
İstanbul Technical University 
Assoc. Prof. Dr. Alper Tunga  
AKARSUBAŞI     .............................. 
İstanbul Technical University 
    
Boğaziçi University Prof. Dr. Gamze TORUN KÖSE  .............................. 
Yeditepe University 
   Assoc. Prof. Dr. Tunç ÇATAL  .............................. 
Üsküdar University 
Pınar HÜNER OMAY, a Ph.D. student of İTU Graduate School of Science 
Engineering and Technology student ID 521062210, successfully defended the 
thesis/dissertation entitled “DIFFERENTIATION OF VESSEL WALL CELLS 
FROM UMBILICAL CORD BLOOD MESENCHYMAL CELLS FOR 
VASCULAR TISSUE ENGINEERING”, which she prepared after fulfilling the 
requirements specified in the associated legislations, before the jury whose signatures 
are below. 
 
 
Date of Submission : 12 January 2016 
Date of Defense : 23 March 2016   
 
vi 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
 
 
 
To my beloved spouse and family, 
 
 
 
viii 
 
 
 
 
 
 
 
 
 
ix 
 
 
FOREWORD 
I am grateful to my supervisor Prof. Dr. Hakan BERMEK for giving me the chance 
to study in this project. I would like to thank for his interest, support and invaluable 
guidance for finding my way through exploration.  
I would like to thank Dr. Aysel YURTSEVER for her pioneering contribution in this 
project and her advise and support.  
I would also like to thank Prof. Dr. Levent TRABZON for his valuable comments 
and ideas. 
Especially, I would like to thank my labmates Merve ZUVİN and Semra Zuhal 
BİROL for their kindless helps and friendship. I have learnt lots of things from them. 
I am sure that this project has taught us to be patient in the life.  
I would like to thank to my dear friends at ONKİM Stem Cell Technologies for their 
amazing help. I know that they always believed in me.  
I am also thankful to Ayşenaz TAVŞANLI for sharing happy, serious and stressfull 
moments with me. Whenever I needed, she was always on the end of the line. I 
believe that we are a good team. 
I would like to thank Cumhur OMAY for making me laughing whenever I feel 
worried. I should thank him forever, for being emotional crutch for always being at 
hand to listen and support my choices. 
Lastly, I would like to thank my parents who make it possible for me to be here, give 
their endless love and showed their patience every time. They always supported my 
academic career. 
We fully acknowledge to the financial support from TUBITAK project (109S296). 
 
 
 
 
March 2016 
 
Pınar HÜNER OMAY 
(Medical Biologist) 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
TABLE OF CONTENTS 
Page 
FOREWORD ............................................................................................................. ix 
TABLE OF CONTENTS .......................................................................................... xi 
ABBREVIATIONS ................................................................................................. xiii 
LIST OF TABLES ................................................................................................... xv 
LIST OF FIGURES ............................................................................................... xvii 
SUMMARY ............................................................................................................. xix 
ÖZET ........................................................................................................................ xxi 
1. INTRODUCTION .................................................................................................. 1 
1.1 Tissue Engineering ............................................................................................. 2 
1.1.1 Vascular tissue engineering ........................................................................ 4 
1.1.1.1 Vessel structure .................................................................................... 6 
1.2 Stem Cells .......................................................................................................... 8 
1.2.1 Embryonic stem cells .................................................................................. 9 
1.2.2 Fetal stem cells .......................................................................................... 10 
1.2.3 Adult stem cells ......................................................................................... 10 
1.2.3.1 Mesenchymal stem cells .................................................................... 12 
1.3 Scaffolds for Vascular Tissue Engineering ...................................................... 16 
1.3.1 Essential properties ................................................................................... 18 
1.3.2 Polydimethylsiloxane (PDMS) as a scaffold for vascular tissue 
engineering ......................................................................................................... 18 
1.4 Aim of the Study .............................................................................................. 20 
2. MATERIALS AND METHODS ........................................................................ 23 
2.1 Materials ........................................................................................................... 23 
2.1.1 Umbilical cord blood samples ................................................................... 23 
2.1.2 Solutions and culture media ...................................................................... 23 
2.1.2.1 Isolation solutions for MSCs .............................................................. 23 
2.1.2.2 Culture media for MSCs .................................................................... 24 
2.1.2.3 Culture media for ECs ........................................................................ 25 
2.1.3 Antibodies ................................................................................................. 25 
2.1.3.1 Antibodies for MSCs.......................................................................... 25 
2.1.3.2 Antibodies for ECs ............................................................................. 26 
2.1.4 Dyes .......................................................................................................... 26 
2.1.5 Chemicals .................................................................................................. 26 
2.1.6 Growth factors ........................................................................................... 26 
2.1.7 Laboratory equipment ............................................................................... 27 
2.2 Methods ............................................................................................................ 28 
2.2.1 Collection of UCB samples ....................................................................... 28 
2.2.2 Collection of native vessel samples .......................................................... 28 
2.2.3 Isolation of MSCs from UCB  .................................................................. 28 
2.2.4 Mononuclear cell counting ........................................................................ 29 
xii 
 
2.2.5 Culture and expansion conditions of UCB derived MSCs ........................ 30 
2.2.6 Immune phenotypic analysis of UCB derived MSCs ............................... 30 
2.2.7 Endothelial differentiation of UCB derived MSCs ................................... 31 
2.2.8 Isolation of ECs from native vessels ......................................................... 32 
2.2.9 Immune phenotypic analysis of ECs ......................................................... 32 
2.2.10 Design and fabrication of PDMS ............................................................ 32 
2.2.11 Plating and culturing of ECs on PDMS substrates .................................. 36 
2.2.12 Cell proliferation and viability analysis .................................................. 36 
2.2.13 Stress induced rolling membrane (SIRM) technique .............................. 37 
2.2.14 Optimization of SIRM technique ............................................................ 38 
2.2.15 Rolling the tubes...................................................................................... 38 
2.2.16 Optimization of sterilization.................................................................... 38 
2.2.17 Microscopic analysis of PDMS samples ................................................. 39 
2.2.18 Contact angle analysis of PDMS samples ............................................... 39 
3. RESULTS .............................................................................................................. 41 
3.1 Isolation and Cultivation of MSCs from UCB ................................................. 41 
3.2 Immune Phenotypic Analysis of MSCs ........................................................... 43 
3.3 Endothelial Differentiation with VEGF ........................................................... 45 
3.4 Immune Phenotypic Analysis of Differentiated ECs cultured with EndoCult-
Kit ........................................................................................................................... 49 
3.5 Immune Phenotypic Analysis of Differentiated ECs cultured with Standard 
Medium................................................................................................................... 49 
3.6 Comparison of Immune Phenotypic Analysis of Differentiated and Native 
Vessel derived ECs ................................................................................................. 50 
3.7 Design of PDMS Patterns ................................................................................. 54 
3.8 Production of Different Designs of Cross-shaped PDMS Membranes ............ 56 
3.9 SIRM Technique .............................................................................................. 58 
3.10 Optimization of the SIRM Technique ............................................................ 61 
3.11 PDMS Surfaces after SIRM Technique  ........................................................ 62 
3.12 Optimization of Sterilization .......................................................................... 65 
3.13 Water Contact Angle Measurements .............................................................. 66 
4. DISCUSSION AND CONCLUSION .................................................................. 68 
REFERENCES ......................................................................................................... 76 
CURRICULUM VITAE .......................................................................................... 84 
 
 
 
 
 
xiii 
 
ABBREVIATIONS 
α-MEM : α-minimum essential medium  
ALCAM : Activated leukocyte cell adhesion molecule 
ANT  : Altered nuclear transfer 
CPD  : Citrate phosphate dextrose 
DI  : Deionized water 
DMEM : Dulbecco’s modified Eagle’s medium 
DMSO : Dimethyl sulfoxide 
EC  : Endothelial cell 
EDTA  : Ethylenediaminetetraacetic acid 
ESC  : Embryonic stem cell 
FBS  : Fetal bovine serum 
FCS  : Fetal calf serum 
G-CSF : Granulocyte colony stimulating factor 
GMP  : Good Manufacturing Practice 
HBSS  : Hanks’ Balanced Salt Solution 
HLA  : Human leukocyte antigen 
HSC  : Hematopoietic stem cells 
ICAM  : Intercellular adhesion molecule 
IGF  : Insulin like growth factor 
IR  : Innermost round 
ISCT  : International Society for Cellular Therapy 
IVF  : In vitro fertilization 
LFA  : Leukocyte function-associated antigen 
MSC  : Mesenchymal stem cell 
PBS  : Phosphate buffered solution  
PCL  : Polycaprolactone 
PDMS  : Polydimethylsiloxane  
PECAM : Platelet/endothelial cell adhesion molecule 
PET  : Polyethyleneterephthalate  
PEUU  : Poly(ether urethane urea) 
PGA  : Polyglycolic acid  
PLA  : Polylactic acid 
PTFE  : Polytetrafluoroethylene  
PU  : Polyurethane 
SIRM  : Stress-induced rolling membrane technique  
SMC  : Smooth muscle cell 
TEBV  : Tissue-engineered blood vessel 
UC  : Umbilical cord 
UCB  : Umbilical cord blood 
UV  : Ultraviolet  
VCAM : Vascular cell adhesion molecule 
VEGF  : Vascular endothelial growth factor 
VEGFR : Vascular endothelial growth factor receptor 
xiv 
 
 
xv 
 
LIST OF TABLES 
Page 
Table 1.1 : Tissue engineering applications are being applied to a variety of tissues 
and organs ................................................................................................. 3 
Table 1.2 : Different types of polymers for vascular tissue engineering .................. 17 
Table 2.1 : Components of McCoy’s Medium .......................................................... 24 
Table 2.2 : Laboratory equipment ............................................................................. 27 
Table 3.1 : The quantity of the elongation after manual production of PDMS  
membranes .............................................................................................. 58 
Table 3.2 : Elongation by a stretcher following the production of PDMS membranes
 ................................................................................................................. 59 
Table 3.3 : The radius of IR is related to tensile strain ............................................. 61 
Table 3.4 : Dimensions of the structures after SIRM technique ............................... 62 
 
 
xvi 
 
 
 
 
 
 
 
 
 
xvii 
 
LIST OF FIGURES 
Page 
Figure 1.1 : In vitro and in vivo tissue engineering process. ...................................... 4 
Figure 1.2 : Schematic illustration of in vitro, in vivo and in situ tissue engineering 
strategies of vascular grafts...................................................................... 5 
Figure 1.3 : Blood vessel structure. ............................................................................ 7 
Figure 1.4 : Three main cell types reside in blood vessel. .......................................... 8 
Figure 1.5 : Stem Cell Classification. ......................................................................... 9 
Figure 1.6 : The mesengenic process. ....................................................................... 13 
Figure 1.7 : Immunomodulatory properties of MSCs. .............................................. 14 
Figure 1.8 : UCB-derived MSCs at 20 days (left) and 12 days (right) both at 10x. . 15 
Figure 1.9 : Expression markers for UCB-derived MSCs. ....................................... 16 
Figure 1.10 : PDMS Structure.  ................................................................................ 19 
Figure 1.11 : Schematic diagram of PDMS forming. ............................................... 20 
Figure 2.1 : Components of McCoy’s Medium. ....................................................... 25 
Figure 2.2 : Crosslinking of unwanted cells to red blood cells. ................................ 28 
Figure 2.3 : Isolation of MSCs. ................................................................................. 29 
Figure 2.4 : A small scale experiment containing different VEGF ratios................. 31 
Figure 2.5 : Endothelial differentiation with two different VEGF rations (Control 
group, 50 ng/mL and 55 ng/mL VEGF).  .............................................. 32 
Figure 2.6 : Microfabrication procedure. .................................................................. 34 
Figure 2.7 : Designs of PDMS pattern formations. .................................................. 34 
Figure 2.8 : Designs of cross-shaped PDMS patterns produced after getting first 
experimental results.  ............................................................................. 35 
Figure 2.9 : Designs of PDMS pattern formations produced after getting the first 
experimental results. .............................................................................. 35 
Figure 2.10 : SIRM technique.  ................................................................................. 37 
Figure 2.11 : The top membrane was produced manually. ....................................... 37 
Figure 2.12 : Stress was produced by a stretcher. ..................................................... 38 
Figure 3.1 : Fibroblastoid and adherent UCB-MSCs (x20, 22nd day).  ................... 41 
Figure 3.2 : Morphology of MSCs cultured in Standart Medium showed 
fibroblastoid and adherent morphology (x20, passage 1).  .................... 42 
Figure 3.3 : Expression profiles of cell surface markers on MSCs. (a) anti-CD34/45; 
(b) anti-CD90; (c) anti-CD44. ............................................................... 44 
Figure 3.4 : Distribution of expression profiles for different passages.  ................... 45 
Figure 3.5 : Small-scale experiment to show the effect of different concentrations of 
VEGF. .................................................................................................... 45 
Figure 3.6 : Growth in the presence of various VEGF concentrations on the 5
th 
day 
of culturing.(C is the control group without VEGF).  ........................... 47 
Figure 3.7 : Growth in the presence of various VEGF concentrations on the 13t
h
 day 
of culturing. (C is the control group without VEGF).  .......................... 48 
Figure 3.8 : Distribution of expression profiles of samples cultured with EndoCult-
Kit
®
. ....................................................................................................... 49 
xviii 
 
Figure 3.9 : Distribution of expression profiles of samples cultured with Standard 
Medium.  ................................................................................................ 50 
Figure 3.10 : Histogram results of native vessel derived ECs and UCB-differentiated 
ECs.  ....................................................................................................... 51 
Figure 3.11 : Comparison of endothelial markers for UCB-MSC derived ECs and 
native vessel-derived ECs.  .................................................................... 53 
Figure 3.12 : Optical microscopic images of patterned PDMS samples. (A) P50; (B) 
C50; (C) S50; (D) L50; (E) P100; (F) C100; (G) S100; (H) L100.  ...... 55 
Figure 3.13 : Cell viability and proliferation of ECs on PDMS scaffolds.  .............. 56 
Figure 3.14 : Optical microscopic images of cross-shaped patterned PDMS samples 
(A) P50; (B) P80; (C) P100; (D) P120; (E) P150.  ................................ 57 
Figure 3.15 : Cell viability and proliferation of ECs on newly designed PDMS 
scaffolds.  ............................................................................................... 57 
Figure 3.16 : After rolling of the PDMS membranes. ............................................... 58 
Figure 3.17 : Thickness of the rolled PDMS sample produced by manually 
elongation. .............................................................................................. 59 
Figure 3.18 : PDMS membrane was produced by a stretcher. .................................. 60 
Figure 3.19 : Thickness of the rolled PDMS sample produced by a stretcher. ......... 60 
Figure 3.20 : Relationship between tensile elongation and the radius. ..................... 61 
Figure 3.21 : Cross-shaped PDMS substrates after SIRM technique.  ..................... 63 
Figure 3.22 : Circular-shaped, square/diamond shaped and straight-linear shaped 
PDMS substrates after SIRM technique. ............................................... 64 
Figure 3.23 : Cell viability and proliferation of ECs on PDMS scaffolds produced by 
SIRM technique.  ................................................................................... 65 
Figure 3.24 : Representative image of the water contact-angles on fabricated PDMS 
surfaces. ................................................................................................. 66 
Figure 3.25 : Contact angle (in degrees) of water on different PDMS substrates.  .. 66 
 
 
  
 
 
  
 
 
 
 
 
xix 
 
DIFFERENTIATION OF VESSEL WALL CELLS FROM UMBILICAL 
CORD BLOOD MESENCHYMAL CELLS FOR VASCULAR TISSUE 
ENGINEERING 
SUMMARY 
In developed countries, cardiovascular diseases are the leading cause of mortality. In 
the USA, coronary artery diseases cause more than 54% of cardiovascular disease-
related deaths. Recently, the use of synthetic grafts (such as ePTFE and Dacron) has 
been in focus to develop blood vessel substitutes. However, the small diameter grafts 
(< 6 mm) fails to replace vessels because of the early formation of thrombosis. 
Further, these materials have poor growth potential and long-term results, such as 
stenosis, thromboembolization, calcium deposition and infection. Therefore, tissue 
engineering has been a new and promising approach to treat cardiovascular disease.  
Vessel engineering is one of the branches of tissue engineering. It was first reported 
in 1986 by Weinberg and Bell and there has been considerable progress in the area of 
vascular engineering. Tissue engineered blood vessels should be functional. They 
should not cause immunogenic and thrombogenic effects. They must be compatible 
with high blood flow rates. Moreover, these scaffolds should have similar 
viscoelasticity to native vessels and be able to integrate well.  
In the past few years, stem cells have been the major cell source in tissue 
engineering. One of the advantages of stem cell theraphy is the elimination of tissue 
rejection because they come from the patient’s blood. Expansion potential and 
differentiation capacity make mesenchymal stem cells more attractive in tissue 
engineering applications. Adult mesenchymal cells can be used to build various types 
of cells/tissues by proliferating in vitro conditions and using tissue engineering 
methods. The most important application of these cells in medicine is tissue-organ 
treatment and regeneration. 
Polydimethylsiloxane is included in a group of polymeric organo-silicon compounds 
that are commonly referred to as silicones. Polydimethylsiloxane is the most widely 
used silicon-based organic polymer. It is known for its biocompability, optically 
clear, inert, non-toxic and non-flammable properties.  
In the current study, mesenchymal cells obtained from umbilical cord blood were 
successfully differentiated into endothelial cells, in vitro, with the help of vascular 
endothelial growth factor, using good manufacturing practice conditions. The 
differentiation was assessed visually via microscopy as well as by detection of 
specific cell surface markers using flow cytometry. The optimum vascular 
endothelial growth factor dosage was 50 ng/mL for efficient stem cell differentiation. 
The effect and importance of the surface modifications on differentiation of 
endothelial cells from umbilical cord blood-derived mesenchymal stem cells and 
proliferation capability were investigated using polydimethylsiloxane scaffolds as the 
surface for cell growth. Polydimethylsiloxane surfaces were constructed to contain 
repeating various surface patterns. Twelve different repeating patterns were 
xx 
 
designed, such as straight lines, cross-shapes, circular shapes or square/diamond 
shapes. Cell viability analysis showed that polydimethylsiloxane surfaces with 
protruding cross-shaped structures provided the highest cell viability/proliferation 
support, providing an 80% increase of cell viability.  
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DAMAR DOKU MÜHENDİSLİĞİ AMACIYLA KORDON KANI 
MEZENKİMAL HÜCRELERİNDEN DAMAR DUVARI HÜCRESİ 
FARKLILAŞMASI 
ÖZET 
Batı ülkelerinde, küçük ve orta boyutlu kan damalarını etkileyen kardiyovasküler 
hastalıklar en başta gelen ölüm nedenidir. Amerika’da koroner arter hastalıklar %54 
ten daha fazla oranda kardiyovasküler ile ilişkili ölümlere neden olmaktadır.  Avrupa 
Kardiyovasküler Hastalık İstatistiklerine göre, kardiyovasküler hastalıklar Avrupa’da 
4 milyon, Avrupa Birliği’nde 1,9 milyon ölüme neden olmaktadır. Son zamanlarda, 
sentetik greftlerin kullanımı (ePTFE ve Dacron gibi) kan damarı benzeri yapıların 
geliştirilmesine odaklanmıştır. Bununla birlikte, 6 mm’den küçük damar greftleri 
erken tromboz gelişiminden dolayı damar değişimlerinde yetersiz olmaktadır. Aynı 
zamanda bu materyaller düşük büyüme potansiyeline ve uzun vadede stenoz, 
tromboembolizm, kalsiyum birikimi ve enfeksiyona neden olmaktadır.  Bu nedenle, 
doku mühendisliği kardiyovasküler hastalıkların tedavisinde yeni ve umut vadedici 
bir yaklaşımdır.  
Doku mühendisliği mühendislik ve yaşam bilimlerini bir araya getiren interdisipliner 
bir alan olarak tanımlanmaktadır. Amacı biyoloji ve mühendislik stratejilerini 
kullanarak organ ve doku fonksiyonlarının iyileştirilmesi ile klinik problemlerin 
çözülmesidir. Doku mühendisliğinin ana bileşenleri hücreler, moleküler sinyaller ve 
özelleşmiş yapı iskeletleridir. Hücre dışı kültür aşamasını takiben, oluşturulmuş 
yapay organ veya doku vücuda entegre edilmekte, bu yapı kan damarları tarafından 
nüfuz edilmekte ve yeni doku büyümesi desteklenmektedir. 
Damar mühendisliği doku mühendisliğinin dallarından biridir. Damar mühendisliği 
yaklaşımı biyomühendislik, doku mühendisliği, damar biyolojisi, kök hücre 
biyolojisi ve biyomalzeme teknolojilerini birleştirerek organ ve dokuların 
yenilenmesini sağlamaktadır. İlk kez 1986 yılında Weinberg ve Bell tarafından 
damar mühendisliğinde umut vaadedici bir gelişme olarak rapor edilmiştir. Doku 
mühendisliği ile oluşturulmuş kan damarları fonksiyonel olmalı, immünojenik ve 
trombojenik etkilere neden olmamalı,  yüksek kan akış oranlarına uygunluk 
göstermeli, normal damara benzer  viskoelastik özellik göstermeli ve vücuda entegre 
olmalıdır.  
Son yıllarda, kök hücreler doku mühendisliği alanında en büyük kaynak olarak yer 
almaktadır. Kök hücre tedavisinin en önemli avantajlarından biri hastanın kendi 
vücudundan izole edildiğinden dolayı doku reddinin olmamasıdır. Çoğalma 
potansiyeli ve farklılaşma kapasitesi, mezenkimal kök hücreleri doku mühendisliği 
uygulamalarında ön plana çıkarmaktadır. Mezenkimal kök hücreler vücutta yaygın 
olarak kemik iliği, yağ dokusu, kordon, iskelet kasları, dermis, perisitler, akciğer 
dokusu, diş pulpası ve periodontal ligamentlerde bulunmaktadır. Mezenkimal kök 
hücreler T lenfositleri, B lenfositleri, doğal öldürücü hücreler ve dendritik hücreler 
gibi çibrçok immün sistem hücreleri ile iletişim halindedir. Erişkin mezenkimal 
hücreler in vitro koşullarda çoğaltılarak ve doku mühendisliği metodları kullanılarak 
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farklı hücre/doku tipleri oluşturulmak amacıyla kullanılmaktadır.  Tıpta bu hücrelerin 
en önemli uygulaması doku-organ tedavisi ve yenilenmesidir. Kemik iliği 
mezenkimal kök hücre açısından zengin bir kaynak olsa da, son yıllarda yapılan 
çalışmalar bu hücrelerin göbek kordon kanında da bulunduğunu göstermiştir. Göbek 
kordon kanı, göbek kordon veninden doğum sonrasında toplanmaktadır. Göbek 
kordon kanı kaynaklı mezenkimal kök hücreler kemik iliğinde olduğu gibi 
farklılaşma potansiyeline sahiptirler. Diğer hücre kaynakları ile karşılaştırıldığında 
kordon kanı eldesi oldukça kolay ve ağrısız bir yöntemdir.  
Hücreler büyümeyi ve farklılaşmayı sürdürebilmeleri için iki boyutlu ya da üç 
boyutlu yapı iskeletlerine ihtiyaç duymaktadırlar. Doku mühendisliğinin diğer 
bileşeni hücrelerin büyüyebileceği bir ortam olan biyolojik ya da biyo-yıkılabilir yapı 
iskeletlerinin kullanımıdır. Yapı iskeletleri doğal (kollajen, fibrin) ya da sentetik 
polimerler (poliglikolid, polilaktid) olabilir. Yapı iskeletleri implantasyon sonrası 
yıkılabilir olmalı ve yerini yeni dokuya bırakmalıdır. Polidimetilsiloksan silikon 
olarak adlandırılan polimerik organo-silikon grubu içerisinde yer almaktadır. 
Polidimetilsiloksan en sık kullanılan silikon temelli organik polimerdir. 
Biyouyumluluk, optik gözlem, toksik ve yanıcı etkisi olmayan özellikleri ile 
bilinmektedir. 
Bu çalışmada, yoğunluk farkı metodu sayesinde izole edilen göbek kordon kanı 
kaynaklı mezenkimal hücreler, MesenCult®  Besiyeri veya Standart Besiyeri olmak 
üzere iki farklı besiyerinde kültüre edilmiş ve büyüme karakteristikleri incelenmiştir. 
Buna karşılık büyümenin Standart Besiyeri’nde daha hızlı olduğu gözlenmiştir. 
Kordon kanından izole edilen mezenkimal hücreler mikroskobik olarak incelenmiş, 
hücre yüzey antijenlerinin ekspresyonu akım sitometri ile gösterilmiştir. Bunun yanı 
sıra izole edilen kordon kanı kaynaklı mezenkimal hücrelerin gerek mikroskobik 
gerek akım sitometrik analizleri bu hücrelerin kemik iliği kaynaklı mezenkimal 
hücrelerle aynı özellikte olduğunu göstermiştir.  
Çalışmada göbek kordon kanından izole edilen mezenkimal hücreler, vasküler 
endotel büyüme faktörü yardımıyla, iyi üretim uygulamaları koşullarında, in vitro 
ortamda endotel hücrelere başarıyla farklılaştırılmıştır. Farklılaşma, mikroskobik 
yöntemin yanı sıra akım sitometri kullanarak özelleşmiş hücre yüzey 
işaretleyicilerinin analizi ile de gösterilmiştir.  Optimum vasküler endotel büyüme 
faktör miktarı, etkin kök hücre farklılaşması için 50 ng/mL olarak bulunmuştur. 
Yüzey modifikasyonlarının göbek kordonu kaynaklı mezenkimal hücrelerden 
farklılaştırılarak elde edilen endotel hücreler üzerindeki etkisi ve önemi, hücrelerin 
çoğalma kapasitesi polidimetilsiloksan yapı iskeletleri kullanılarak araştırılmıştır. 
Polidimetilsiloksan çizgi, artı, kare ve daire şekillerinde olmak üzere, yüzeyleri 
tekrarlayan farklı geometrik şekiller ve farklı derinlikler içerecek şekilde üretilmiştir. 
İki boyutlu olarak üretilen ve canlılık analizleri gerçekleştirilen yapı iskeletleri aynı 
zamanda, SIRM tekniği kullanılarak üç boyutlu olarak üretilmiştir. Hücre canlılık 
analizi, bu yüzeylerde büyütülmüş polidimetilsiloksan yüzeyler arasında artı şekilli 
yapı iskeletinin %80 oranında canlılığı arttırdığını, en yüksek hücre canlılığı ve 
proliferasyonu sağladığını göstermiştir. Yapı iskeletlerinin sterilizasyonu üç farklı 
yöntem ile test edilmiş ve üç farklı metodun da geometrik şekiller üzerinde herhangi 
bir negatif etkisinin olmadığı gözlenmiştir. Farklı geometrik şekillerde ve 
derinliklerde üretilen yapı iskeletlerinin hidrofobik özelliklerinin her tür içinde aynı 
olduğu gösterilmiştir.  
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Çalışmada doğal damar benzeri yapı iskeletinin üretimi ve bu yapı iskeletlerinin 
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1.  INTRODUCTION 
Every year, ageing populations of the developed countries suffer failure of organ and 
tissues. Organ or tissue loss is treated using transplanting organs from one person to 
another. Although these therapies are still successful and have saved millions lives, 
transplantation and reconstructive surgery options are severely limited (Godara et al., 
2008; Baguneid et al., 2011). Not only organ transplantation but also autologous 
transplantation, where a patient’s own tissue is removed from another site of the 
body for repair or reconstruction, is used to treat organ failure and tissue loss. It is a 
big advantage that autologous transplantations do not cause immune rejection, but 
can result in donor site morbidity (Godara et al., 2008; Kuo and Tuan, 2003). 
Therefore, a new field called tissue engineering can be an ideal solution for the 
replacement of damaged or defected tissues. 
Tissue engineering is an interdisciplinary field that uses cultured human cells for 
maintenance, regeneration, or replacement of malfunctioning tissues (L’Heureux et 
al., 1998; Polak and Bishop, 2006; Lee and Atala, 2014).  Tissue engineering was 
first introduced in 1933 when mouse tumour cells were protected from immune 
attack by implanting into a biocompatible polymer membrane (Kim and Evans, 
2005; Polak and Bishop, 2006). Y. C. Fung, a pioneer of biomechanics and 
bioengineering, first used the term ‘tissue engineering’ in 1985. Langer and Vacanti 
(1993) made a description: “Tissue engineering is an interdisciplinary field that 
applies the principles of engineering and life sciences towards the development of 
biological substitutes that restore, maintain, or improve tissue function” (Bajada et al, 
2008). 
Tissue engineering is made up of three important components: Cells, scaffolds and 
growth factors/signals (Kim and Evans, 2005; Polak and Bishop, 2006). According 
to tissue engineering principle, living and cultured cells are combined with a support 
or scaffold, which can be natural or synthetic. An ideal scaffold should be a 3D 
structure, mimic the same characteristics of the tissue and support cell attachment, 
growth, differentiation and migration (Bajada et al., 2008; Griffith and Naughton, 
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2002; Pountos et al., 2007).   
One of the cell types used in tissue engineering is adult tissue-specific cells. On the 
other hand, because of their limited proliferative capacities, it is difficult to prepare 
them for scaffold seeding. When their cultivation period increases, their functional 
quality decreases (Griffith and Naughton, 2002; Kuo and Tuan, 2003). Therefore, use 
of stem cells and progenitor cells for tissue engineering studies come into 
prominence rather than tissue specific cells (Kuo and Tuan, 2003). Stem cells were 
first used in a study by Becker et al. (1963). In the study, bone marrow cells were 
injected into irradiated mice. It was noticed that nodules developed in the spleens of 
the mice in direct proportion to the number of bone marrow cells injected. It was the 
evidence of stem cell renewal (Bajada et al, 2008). Thus, stem cells have three 
unique properties: 1) they can divide and renew themselves; 2) they are 
unspecialized; 3) they can give rise to different cell lineages under appropriate 
conditions (Bajada et al, 2008; Kuo and Tuan, 2003; Polak and Bishop, 2006).  
As a result, tissue engineering process has become a solution to create a living graft 
capable of biological response and promote regeneration by replacing tissue or organ 
function with constructs that contain functional stem cells (Nugent and Edelman, 
2003; Cleary et al., 2012). 
1.1 Tissue Engineering 
The term ‘tissue engineering’ was first introduced by National Science Foundation at 
a meeting in 1987 (Sarkar et al., 2009). This presentation gave rise to the first tissue 
engineering meeting in the next year. Although there were preliminary studies with 
cells and materials in the seventies and eighties, tissue engineering studies have 
emerged in the early nineties with replacement, repair and regeneration of failing 
organs (Sarkar et al., 2009; Seif-Naraghi and Christman, 2013). The first review of 
tissue engineering was published in Science in 1993 by Langer and Vacanti (Seif-
Naraghi and Christman, 2013).  
Tissue engineering is described as ‘an interdisciplinary field that applies the 
principles of engineering and life sciences towards the development of biological 
substitutes that restore, maintain, or improve tissue function or a whole organ’ by 
Langer and Vacanti (Kirton et al., 2011; Liu et al., 2007). It aims to solve clinical 
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problems by restoring organ or tissue function with the help of biological and 
engineering strategies (Kingsley et al., 2013). Although artificial protheses and 
mechanical devices save the lives of millions of people, their integration with the 
host tissue causes a host immune response and damages healthy tissue around the 
implant. Surgical reconstruction of organs and tissues which is another strategy 
causes surgical complications and morbidity at the donor site. In an attempt to 
overcome these limitations, tissue engineering strategy has emerged as a new 
approach to provide tissue and organ transplantation (Sarkar et al., 2009). Table 1.1 
shows the concept of the tissue engineering which is being applied to a variety of 
tissues and organs. 
Table 1.1 : Tissue engineering applications are being applied to a variety of tissues 
and organs (Nerem and Ensley, 2004). 
  
Severe burns Blood vessels 
Skin ulcers Heart valves 
Facial reconstruction Myocardial pathces 
Cartilage Heart 
Tendons Bioartificial pancreas 
Ligaments Kidney 
Bone Liver 
The main principle of tissue engineering is to combine cells with natural or synthetic 
three-dimensional scaffolds by means of growth factors and extracellular matrix 
(Kim and Evans, 2005; Sarkar et al., 2009). After in vitro cultuvation period, the 
artificial organ or tissue is implanted into the body (Liu et al., 2007). The structure 
was infiltrated by blood vessels and the new tissue growth is directed and oriented by 
the body’s natural ability (Atala, 2007). Figure 1.1 shows the tissue engineering 
process both in vitro and in vivo. 
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Figure 1.1 : In vitro and in vivo tissue engineering process (Sarkar et al., 2009).             
A) Biocompatible scaffold material is combined with appropriate 
growth factors and cells in in vitro conditions. B) Production of 
transplantable graft provides the recruitment and reorganization of 
host cells in the body and tissue regeneration. 
1.1.1 Vascular tissue engineering 
In western countries, cardiovascular diseases affecting small and medium-sized 
blood vessels are the major cause of death (Williamson et al., 2006; Hasan et al., 
2014; Li et al., 2014). In USA, 1.4 million people need prostheses each year and 
600,000 people die because of heart diseases (Hasan et al., 2014; Li et al., 2014). 
According to the European Cardiovascular Disease Statistics, cardiovascular diseases 
cause 4 million deaths in Europe and 1.9 million deaths in the European Union (Url-
1).  
Atherosclerosis is the most common cardiovascular problem, in the form of coronary 
artery and peripheral vascular disease (Williamson et al., 2006). It causes plaque 
formation and reducing the cross-sectional area available for blood flow. This results 
in decreasing of blood flow, stenosis, vessel occlusion, tissue ischemia and stroke 
(Hasan et al., 2014; Li et al., 2014).  Eventually, surgeries such as replacement of 
blood vessels become inevitable. Although current treatment methods contain 
transplantations of autologous saphenous veins and internal mammary arteries, they 
are generally restricted because of previous surgeries or vessel diseases (Zhang et al., 
2007; Bourget et al., 2012). Another solution such as tissue or organ donation has 
also problems because of donor shortages for the transplant surgery (Langer and 
Vacanti, 1993). To overcome these problems, the large diameter vessels (>6 mm) 
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were tried to be developed by using autologous/allogeneic vessel transplantations or 
treatment with synthetic grafts to improve life expectance of patients (Boland et el., 
2004). On the other hand, finding the correct sized sample from patient or donor 
becomes harder for small diameter vessels (<6 mm). The other problem is the 
occlusion of synthetic materials and their inability to resist to the blood flow pressure 
(Niklason et al., 1999). Unfortunately, these grafts have failed to function 
successfully; because of their inability to recover the damage (Nugent and Edelman, 
2003), early thrombosis formation (Brewster et al., 2007; Gao et al., 2008), chronic 
inflammation, microbial infection (Hoerstrup et al., 2001). New drugs and devices 
were tried to decrease mortality rates; yet, they were inefficient (Nugent and 
Edelman, 2003). As a result, vascular tissue engineering has emerged as a vital area 
(Fernandez et al., 2014; Li et al., 2014).  
Vascular tissue engineering process is composed of three strategies, including in 
vitro, in vivo, and in situ tissue engineering (Figure 1.2). In vitro tissue engineering 
process is a traditional approach that combines functional cells, appropriate scaffolds 
and bioreactors. In vivo tissue engineering approach aims to grow autologous grafts 
by using the tissue environment of the body as a bioreactor. In situ tissue engineering 
approach does not need any in vitro culture process and the scaffolds can be either 
acellular or seeded with cells (Li et al., 2014).  
 
Figure 1.2 : Schematic illustration of in vitro, in vivo and in situ tissue 
engineering strategies of vascular grafts (Li et al., 2014). 
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Vascular tissue engineering approach combines the technologies of bioengineering, 
tissue engineering, vascular biology, stem cell biology and biomaterials to repair or 
regenerate tissues and organs by using cells and scaffolds (Li et al., 2014). 
Historically, Weinberg and Bell produced the first tissue-engineered blood vessel 
(TEBV) in 1986 (Cleary et al., 2012). They used bovine endothelial cells (ECs), 
smooth muscle cells (SMCs) and fibroblasts with a collagen matrix. On the other 
hand, the study had some limitations such as the inability of the collagen matrix to 
withstand physiologic burst pressures (Cleary et al., 2012). This issue has become a 
research focus over the past decades. There are key challenges to produce functional 
TEBVs:  
 production of nonthrombogenic, nonimmunogenic and biodegradable 
surfaces, 
 achieving low incidence of infectious complications, 
 resisting degradation, 
 providing better mechanical strength, 
 designing a scaffold which is suitable with pulsatile blood pressures,  
 selection of suitable cell type and source,  
 cost effectiveness, 
 ready availability for use (Fernandez et al., 2014; Benrashid et al., 2015). 
1.1.1.1 Vessel structure 
The circulatory system is the first that is formed within the embryo. While powering 
of blood flow is provided by the heart, the blood is distributed to other organs by the 
vessels. Blood vessels are formed by a three-layered wall structure consisting of an 
intima, media and adventitia (Figure 1.3).  
The intima is the innermost layer and borders the vessel lumen. A single layer of ECs 
called as endothelium and a thin layer of collagen and elasting fibers called as the 
basement membrane form the innermost layer. Regulation of vascular permeability 
and prevention of thrombus formation are performed by the endothelium (Kirton et 
al., 2011).   
ECs, which are the vital component of blood vessels, function at the interface 
between the constituents of the blood and the vessel wall (Figure 1.4) (Anderson and 
Hinds, 2011). ECs have lots of physiologic functions in vivo. Promotion of 
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thromboresistance is their most important function. The presence of ECs on synthetic 
scaffolds as a confluent monolayer provides improving thromboresistance while 
preventing the development of pseudointimal hyperplasia (Naito et al., 2011). The 
lack of viable ECs on artificial grafts cause thrombogenicity and promotes intimal 
proliferation within the graft. EC seeding of synthetic grafts has been attempted to 
moderate these limitations (Nugent and Edelman, 2003). 
 
 
 
Figure 1.3 : Blood vessel structure. Pictures taken from 'Netter's Atlas of Human 
Physiology' by J.T. Hansen and 'Molecular regulation of vessel 
maturation'  by R.K. Jain (Nature Medicine, 2003).  
The pioneering study for EC seeding on prosthetic materials was conducted in 1978 
by Heering. ECs were harvested from vein segments by scraping the luminal surface. 
Since then, different sources and types of cells, graft materials, graft designs, and 
coating of grafts have been evaluated.  Along with the continued emphasis on the 
endothelialization of synthetic vascular grafts, alternative cell types have been used 
to promote endothelialization (Naito et al., 2011). 
The intima is surrounded by the middle wall layer called as the media. In this layer, 
elastic laminae alternates with the layers of SMCs (Kirton et al., 2011).  
The adventitia is the outer layer. It formes a connective tissue incorporating 
longitudinally orientated collagen and elastin, which support the vessel. Except small 
arterioles, this layer is present in all arterial vessels. This layer is consisting of 
fibroblasts whose function is synthesizing collagen and elastin, pericytes and 
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mesenchymal precursor cells of vascular smooth muscle and vasa vasorum (Kirton et 
al., 2011).  
 
Figure 1.4 : Three main cell types reside in blood vessel (Anderson and Hinds, 
2011). 
1.2 Stem Cells 
According to old botanical monographs, ‘stem’ was used for the apical root 
meristems. They are populations of cells at the root that divide and form all the 
tissues of the root (Bongso and Richards, 2004; Witkowska-Zimny and Wrobel, 
2011). At the present time, stem cells are used to define undifferentiated cells 
(Vallone et al., 2013; Wagers and Weissman, 2004).  
Stem cells can be defined by two essential properties, i) they have the capacity for 
self renewal and they can give rise to more stem cells, ii) they can differentiate into 
different cell lineages of the germ layer with a phenotype distinct from that of the 
precursor under the influence of appropriate signals (Bajada et al., 2008; Wagers and 
Weissman, 2004; Barry and Murphy, 2004). 
Stem cells can be classified according to their development potential as totipotent, 
pluripotent, multipotent and unipotent stem cells (Figure 1.5). Totipotent stem cells 
can give rise to embryonic and extraembryonic cell types. Pluripotent stem cells can 
give rise to all embryonic cell types. Multipotent stem cells can give rise to a number 
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of cellular lineages. Unipotent stem cells can give rise to only specific cellular 
lineages. (Wagers and Weissman, 2004; Vallone et al., 2013).  
 
Figure 1.5 : Stem Cell Classification (Url-2). 
Embryos, fetuses and adults are the main sources, which stem cells can be isolated 
(Godara et al. 2008; Witkowska-Zimny and Wrobel, 2011). According to their 
origin, they can be classified into four main types: i) embryonic stem cells, ii) fetal 
stem cells, iii) perinatal stem cells, iv) adult stem cells. 
1.2.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are pluripotent cells derived from totipotent cells of the 
inner cell mass of the blastocyst (5-6 day-old)  (Bajada et al., 2008; Martino et al, 
2012; Herberts et al., 2011). They have the potential to differentiate into the three 
germ layers: endoderm, ectoderm and mesoderm (Prasongchean and Ferretti, 2012). 
These cells can exhibit unlimited and undifferentiated proliferation in vitro under the 
appropriate signals. In spite of their proliferation capacity, the mechanisms for self-
renewal and pluripotency are not fully understood (Herberts et al., 2011; Martino et 
al., 2012).  
Mouse ESCs were first described in 1981 at the University of California, San 
Francisco. In 1998, the first human ESC line was obtained by J. Thompson at the 
University of Wisconsin–Madison, USA (Bajada et al., 2008; Herberts et al., 2011).  
When ESCs are compared between two different sources, it is seen that mouse ESCs 
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are capable of proliferating more slowly than human ESCs. While mouse ESCs have 
flat structure, human ESCs form spherical colonies (Polak and Bishop, 2006).  
The discovery of ESCs which yielded detailed information on human development, 
regulation of cellular and molecular mechanisms has lead up to biomedical research 
(Prasongchean and Ferretti, 2012). On the other hand, their clinical usage is restricted 
because of having unlimited ability to proliferate, leading to teratoma formation 
(Bajada et al., 2008; Witkowska-Zimny and Wrobel, 2011). Another obstacle about 
ESCs is ethical concerns due to the destruction of the embryo (Rodriques et al., 
2011).  
The usage of human ESCs varies by different cultures and religious groups. For 
example, while human ESC lines are allowed legally in the UK, Italy, Finland, 
Greece, the Netherlands, Sweden by law under certain conditions, ESC studies and 
use of ESC lines are prohibited in Austria, Germany, France and Ireland (Polak and 
Bishop, 2006; Bajada et al., 2008).aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa. 
1.2.2 Fetal stem cells 
Fetal stem cells can be isolated from the fetus or from the supportive extra-
embryonic structures that are of fetal origin (Pappa and Anagnou, 2009). They can be 
extracted from fetal blood and cultured for 20 to 40 passages. These cells are found 
during the first trimester fetal blood, bone marrow, liver and spleen (Polak and 
Bishop, 2006). 
Studies with fetal stem cells showed that they have a great therapeutic potential in 
cancer treatment with the ability to be transferred to the tumor site and reduce tumor 
burden. 
1.2.3 Adult stem cells 
Due to the unlimited proliferation capability and the risk of teratoma formation of 
ESCs, researchers have started to find new cell sources. In addition to ethical 
concerns, generation of ESCs by in vitro fertilization (IVF) and altered nuclear 
transfer (ANT) are problematic (Zhao et al., 2006; Passier et al., 2008). Therefore, 
adult stem cells or somatic stem cells drew much greater interest.  
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Adult stem cells have greater advantages than ESCs. For example, they are non-
tumorigenic and they can be isolated from either embryonic/foetal or postnatal 
tissues providing to be used for cell maturation and specific diseases, as well as for 
tissue engineering studies (Prasongchean and Ferretti, 2012). 
Adult stem cells are undifferentiated and isolated from various sources including 
amniotic fluid, umbilical cord blood, umbilical cord tissue, adipose tissue, central 
nervous system, bone marrow, retina and skin (Bajada et al., 2008; Polak and 
Bishop, 2006; Witkowska-Zimny and Wrobel, 2011). It is widely known that they 
have lost their pluripotent ability and they retain a multipotent differentiation 
capability (Bajada et al., 2008).  
Adult stem cells can generate mature cells according to their tissue origin; 
hematopoietic stem cells generate blood cells; bone marrow and cord blood-derived 
stem cells generate mesodermal cell types (Kim et al., 2004; Witkowska-Zimny and 
Wrobel, 2011). They can be isolated from peripheral blood after mobilization from 
the marrow by means of granulocyte colony stimulating factor (G-CSF) (Brignier 
and Gewirtz, 2010). In recent years, some transplantation studies revealed that a 
fraction of adult stem cells can generate cells of a different embryonic lineage in 
vitro and in vivo, for example: adipose tissue-derived stem cells have the ability to 
form bone and muscle of a mesodermal lineage; hepatocytes and pancreatic islets of 
an endodermal lineage; and neurons and oligodendrocytes of an ectodermal lineage 
(Witkowska-Zimny and Wrobel, 2011). 
The main role of these cells is to provide tissue development, repair and homeostasis 
(Gomillion and Burg, 2006; Polak and Bishop, 2006; Prasongchean and Ferretti, 
2012).  
Unfortunately, adult stem cells are not able to proliferate like ESCs. Because adult 
stem cells are not as young as ESCs, they may contain more DNA abnormalities 
acquired with age (Witkowska-Zimny and Wrobel, 2011). 
Adult stem cells’ immunogenicity and differentiation potential can vary according to 
their sources and donor characteristics such as age, sex, and genetic history 
(Prasongchean and Ferretti, 2012; Rodrigues et al., 2011). Although they have 
limited proliferative and differentiation capacity, hematopoietic stem cells have been 
used in medicine since 1960s (Polak and Bishop, 2006; Rodrigues et al., 2011). For 
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example, hematopoietic stem cells provide all types of cells in the blood during their 
lifespan. Also, recent studies showed that mesenchymal stem cells from different 
sources have been successfully tested in cell therapy studies (Rodrigues et al., 2011).  
Another advantage led them to use in clinical applications is their autologous usage. 
They can be isolated from one patient’s body and after some manipulations they can 
be transplanted into the same body without any immune rejection (Prasongchean and 
Ferretti, 2012; Passier et al., 2008).  
1.2.3.1 Mesenchymal stem cells 
Hematopoietic stem cells in bone marrow were first identified 130 years ago, in the 
pioneering studies of the German pathologist Cohnheim. His work raised the 
possibility that bone marrow may be the source of fibroblasts that deposit collagen 
fibers as part of the normal process of wound repair (Chamberlain et al., 2007). 
Evidence that the stromal compartment of bone marrow contains cells, is now 
available, starting with the work of Friedenstein and Petrakova (Barry and Murphy, 
2004; Chamberlain et al., 2007).  
The researchers cultured whole bone marrow in plastic culture dishes, after that they 
discarded hematopoietic cells by washing with fresh culture medium. They reported 
that some of the cells were plastic-adherent and heterogeneous in appearance. The 
adherent cells were spindle-shaped and multiply rapidly in the culture (Alhadlaq and 
Mao, 2004; Chamberlain et al., 2007). After subculturing, they gained more 
homogeneous fibroblastic appearance. It was also reported that these cells were able 
to differentiate into the cells of connective tissue lineages, including bone, fat, 
cartilage and muscle (Figure 1.6) (Barry and Murphy, 2004). 
The Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy (ISCT) proposed a set of standards to define human MSCs for both 
laboratory based scientific investigations and preclinical studies. According to the 
criteria, human MSCs must be plastic-adherent for culture plates; be positive for 
CD105, CD73, and CD90 and negative for CD45, CD34, CD14 or CD11b, CD79a, 
or CD19 and HLA-DR; and must be able to differentiate to osteoblasts, adipocytes, 
and chondroblasts under standard in vitro differentiating conditions (Salem and 
Thiemermann, 2010). 
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Figure 1.6 : The mesengenic process (Caplan, 2013). 
MSCs were isolated and characterized in many other species, including murine, 
lapine, canine, ovine, avian, porcine, equine, and bovine (Alhadlaq and Mao, 2004). 
Human MSCs can be typically isolated by the help of density gradient centrifugation. 
Fetal bovine serum (FBS) and fetal calf serum (FCS) are the most commonly used 
supplements for in vitro cultivation of MSCs (Chamberlain et al., 2007; Osipova et 
al., 2011). Not only FBS but also FCS contains a lot of factors that stimulate cell 
growth (nutrients, growth factors, etc.). Most preclinical studies and more than 10 
clinical protocols used growth medium containing 10-20% FCS for the cultivation of 
MSCs. On the other hand, when they are used for clinical purposes, animal-origin 
serum has some risks because of xenogeneic antigens and transmission of animal 
viruses and prions. Besides, bovine proteins and peptides could be conjugated to 
MSC, and subsequently induce an immune response, especially after repeated 
injections of MSC as well as subsequently cause rejection of transplanted cells 
(Osipova et al., 2011). As a result, human-compatible serum or serum-free culture 
medium is a good alternative during the expansion of MSC for clinical use.  
Although MSCs phenotypically express a number of markers, none of them are 
specific to MSCs. It is widely accepted that adult human MSCs do not express the 
hematopoietic markers CD45, CD34, CD14, CD11, costimulatory molecules CD80, 
CD86, or CD40 or the adhesion molecules CD31 (platelet/endothelial cell adhesion 
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molecule [PECAM]-1), CD18 (leukocyte function-associated antigen- 1 [LFA-1]), or 
CD56 (neuronal cell adhesion molecule-1). On the other hand, they can express 
CD105 (SH2), CD73 (SH3/4), CD44, CD90 (Thy-1), CD71, and Stro-1 as well as 
the adhesion molecules CD106 (vascular cell adhesion molecule [VCAM]-1), 
CD166 (activated leukocyte cell adhesion molecule [ALCAM]), intercellular 
adhesion molecule (ICAM)-1, and CD29 (Chamberlain et al., 2007; Vallone et al., 
2013; Alhadlaq and Mao, 2004).  
MSCs can interact with a wide range of immune cells, such as T lymphocytes, B 
lymphocytes, natural killer cells and dendritic cells and modulate the functions of the 
immune system by secreting dissoluble cytokines and by direct cell-cell contacts 
(Figure 1.7). When they are in a high number, T-cell proliferation is inhibited. In 
contrast with T-cell proliferation, when they are in a high number, B-cell 
proliferation is increased (Lin et al., 2011).  
 
 
Figure 1.7 : Immunomodulatory properties of MSCs (Lin et al., 2011). 
The human umbilical cord (UC) is a vital organ. It provides oxygen and nutrient 
exchange between the developing embryo and placenta. It is formed by the remnants 
of the embryonic yolk sac and allantois. Two arteries and a single vein form the 
structure of the UC. The mature and progenitor cells are included in the umbilical 
vein. Umbilical cord blood (UCB) is included in the vein and can be collected after 
the birth (Flynn et al., 2007).  
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Although bone marrow has been studied as a major source for MSCs, in recent years, 
UCB-derived MSCs have attracted attention as an alternative source.  The isolation 
potential of MSCs from UCB give them an important potential for tissue engineering 
and cell-based therapies. First example of transplantation was performed in 1988 to 
treat an anemia patient, which suggested that cord blood itself contains sufficient 
amount of hematopoietic stem cells (HSCs) to recover the host lymphohematopoietic 
compartment (D'Alessandro et al., 2010; Kim et al., 2010; Manca et al., 2008). 
As shown in Figure 1.8, UCB-derived MSCs show fibroblastoid structure and form 
colonies within 2-4 weeks............................................................................................... 
    
Figure 1.8 : UCB-derived MSCs at 20 days (left) and 12 days (right) both at 10x 
(Flynn et al., 2007). 
As well as in bone marrow-derived MSCs, UCB-derived MSCs possess the 
capability of multilineage differentiation (Figure 1.9) (Flynn et al., 2007).  
UCB-derived MSCs have also potential for immune modulation, tumor tropism and 
nursing effect. When it is compared with other MSC sources, it widely considered as 
a fascinating source for the usage in clinical applications. This is because, when they 
are compared with bone marrow derived MSCs, they show lower immunogenicity 
owing to primitive characters originating from UCB (Kim et al., 2010). For example, 
UCB-derived MSCs can be successfully transplanted without graft versus host 
diseases because of permission of HLA mismatch degree as distinct from bone 
marrow-derived MSCs. Therefore, under appropriate biological conditions, they 
show low immunogenicity (Kim et al., 2010; Manca et al., 2008).  
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Figure 1.9 : Expression markers for UCB-derived MSCs (Flynn et al., 2007). 
1.3 Scaffolds for Vascular Tissue Engineering 
Cells need a structured 2D or 3D environment for cellular growth and differentiation. 
The basis of tissue engineering strategy is the usage of biological or biodegradable 
scaffolds, on which cells can be grown (Naito et al., 2011).  
Scaffolds fabricated from natural (collagen, fibrin) or synthetic polymers 
(polyglycolide, polylactide, polylactide coglycolide), are porous and biodegradable 
structures (Table 1.2). They can be sponge-like sheets, gels, or highly complex 
structures with intricate pores and channels fabricated using new materials-
processing technologies. Virtually all scaffolds are intended to degrade slowly after 
implantation and be replaced by new tissue (Griffith and Naughton, 2002). 
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Table 1.2 : Different types of polymers for Vascular Tissue Engineering (Nugent 
and Edelman, 2003). 
 
Polymer Surfaces Studied for Vascular Tissue Engineering 
Polytetrafluoroethylene (PTFE) 
ePTFE/denucleated ePTFE  
Dacron  
pHEMA/MMA copolymers 
Polyurethane 
Polyethyleneterephthalate (PET) 
Poly(ether urethane urea) (PEUU) 
Perfluorosulfonic acid (Nafion) 
Polyvinyl chloride 
A wide range of natural proteins, such as collagen, elastin, fibronectin, can be used 
for cell attachment and cell signaling. For example, the first tissue-engineered 
vascular graft was created by Weinberg and Bell in 1986. The researchers cultured 
smooth muscle cells (SMCs) and ECs with the collagen gel, thus they observed a 
confluent and biologically active EC luminal surface. Although they are 
advantageous due to their inherent biological recognition through receptor–ligand 
interactions, cell-mediated proteolysis and remodeling, and low toxicity, the 
mechanics of the grafts are not strong enough to support the physical load because of 
their physical weakness (Zhang et al., 2007).  
Unlike natural proteins, decellularized vessels can maintain good mechanical 
properties of nature vessels. For example, Cho et al. used bone marrow stem cells for 
differentiation into endothelial and vascular smooth muscle cells and three distict 
vessel layers. Decellularization is typically achieved by treating tissues with a 
combination of detergents, enzyme inhibitors and buffers. However, studies found 
that cell migration into these scaffolds was inadequate due to the very tight matrix 
organization (Cho et al., 2005; Zhang et al., 2007; Kumar et al., 2011). As a result, 
designed-biomaterials have been a solution to overcome these challenges. 
Designed-scaffolds have lots of advantages such as controlled mechanical properties 
and degradation kinetics, easy process ability into custom shapes and structures, and 
easy modification of the material for specific applications (Nugent et al., 2003). 
Biodegradable and biocompatible synthetic polymeric scaffolds such as  polylactic 
acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polyurethanes (PU), 
and related copolymers or composites have been extensively studied (Kumar et al., 
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2011). Different techniques can be used to culture the cells with these scaffolds, 
including static seeding, dynamic seeding, vacuum aided seeding, or electrostatic 
seeding.  
1.3.1 Essential properties 
As mentioned before, either synthetic or naturally occurring polymers can be used to 
create scaffolds for vascular tissue engineering applications. In order to select 
appropriate polymers for vascular grafts, it is necessary to understand the cell-
polymer interaction (Naito et al., 2011). An ideal vascular graft should mimic the 
natural vessel. It should be resistant to thrombosis, inflammation, and neointimal 
proliferation.  
As such, the ideal graft should possess the structural integrity of a native vessel and 
resist degradation and adverse remodeling under a variety of pressure conditions. It 
should function metabolically and biochemically like a native vessel, presenting a 
luminal substrate that optimizes healing and circulating cell adhesion (Nugent et al., 
2003). Mechanical properties include burst pressure, fatigue-resistance, suture 
retention, kinking radius, and compliance. Burst pressure and mechanical resistance 
of the vascular graft should be strictly tested to ensure the vascular graft’s durability 
in pressure (Kumar et al., 2011). 
Mechanical properties are equally important as mechanical properties in vascular 
tissue engineering. While the biological reaction can occur acutely after the first 
week or month, chronic reaction can occur over months to years. Therefore, to 
overcome the potential for thrombus formation and prevent non-specific protein 
adsorption, novel scaffold materials can be used by surface modifications or the use 
of ECs (Kumar et al., 2011). 
1.3.2 Polydimethylsiloxane (PDMS) as a scaffold for vascular tissue engineering 
 In the past decade, investigating cellular reactions and behaviors in microfluidic 
environment were used to mimic cardiovascular systems. . Studying the behavior of 
individual cells and cell suspansions were performed by microchannels with different 
geometries and surface topography (Fiddes et al., 2010; Leclerc et al., 2003). 
Different kinds of fabrication methods provided microfluidic channels organized for 
continuous nutrition supply to the cells.  
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PDMS is a silicone elastomer that is studied to build a microfluidic device for the 
purpose of vascular tissue engineering (Leclerc et al., 2003). Figure 1.10 shows the 
chemical structure of PDMS. 
 
Figure 1.10 : PDMS Structure (Url-3). 
PDMS devices have useful properties, they are cost-efficient, biocompatible, non-
toxic and oxygen-permeable. PDMS is also an appropriate material for microscopic 
observations due to its transparent properties (Fiddes et al., 2010; Leclerc et al., 
2003; Mata et al., 2005; Wang et al., 2005). PDMS is flexible, deform under the 
influence of force and gain its shape when the force is released (Flores and Wang, 
2010).  
Different patterned scaffolds can direct cell organization and differentiation. Hence, 
cell alignment can be controlled by micropatterning and nanopatterning tools. For 
example, soft lithography is a suitable method to generate micropatterns on different 
scaffold materials for biological applications. For example, the desired pattern can be 
generated by photolithography onto a silicon wafer, which can be transferred to an 
elastomeric material such as PDMS (Huang and Li, 2008).  
The principle of PDMS patterning process can be seen in Figure 1.11. On top of the 
solid substrate, a photoresist layer such as glass or silicon is deposited and patterned 
by using lithography process. The viscous liquid form of PDMS is poured over the 
surface of the substrate. The surface of the substrate is traversed with a blade and it is 
still in contact with the top surface of the photoresist layer. After removal of 
excessive PDMS, the main PDMS is left only in recessed regions between protruding 
photoresist molds. The photoresist mold is then removed by acetone, after the 
remained PDMS is thermally cured (Flores and Wang, 2010; Ryu and Liu, 2002; 
Chen et al., 2012). 
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Figure 1.11 : Schematic diagram of PDMS forming (Ryu and Liu, 2002). 
1.4 The aim of the study 
Biodegradable and biocompatible polymeric scaffolds for vascular tissue engineering 
are three-dimensional structures that allow cell types to attach and reproduce on 
them.  
Recent studies demonstrated that UCB-derived MSCs have been characterized by 
their multipotency to differentiate into mesenchyme-lineage cell types, including 
chondrocytes, osteoblasts, and adipocytes. Nevertheless, nobody observed the effect 
of PDMS on ECs, which are differentiated from MSCs from human UCB. 
In the scope of thesis, we investigated the effect of PDMS on EC proliferation and 
differentiation upon seeding UCB-derived MSCs, leading to the formation of 
adequate tissue substitutes for vascular defects. With this aim, we isolated MSCs 
from human UCB and cultured them in humidified atmospheric conditions. To 
optimize the cultivation, cells were grown on two different cultivation media and the 
effects of the ingredients were tested by microscopic analysis. Next, microscobic 
analysis was done and characterization of the cells was performed by detection of 
CD34/45, CD90 and CD44 surface markers.  
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For differentiation studies, varying concentrations of vascular endothelial growth 
factor (VEGF) were applied  to find the best growth factor ratio. ECs were grown on 
two different cultivation media as in MSCs and their characterization was done with 
microscopic analysis. Next, their characterization was done with CD106, CD309, 
CD144 and CD44 surface markers. For biocompability studies, flat PDMS as well as 
various patterned PDMS designs were produced to show the effect of topography on 
cell growth/proliferation. It is known that certain sterilization processes might create 
surface and pattern degradation with some scaffold materials. Therefore, three 
techniques were studied to find the effect of sterilization on surface structures.  
A stress-induced rolling membrane technique (SIRM) was performed for the 
production of 3-dimensional (3D) structure. The factors that affect the size of 3D 
structure and the thickness of its wall were tested. The radius of curvature of the 
inner tube was quantified by changing the tensile elongation. 
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2.  MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Umbilical cord blood samples 
UCB samples were collected from women who gave birth in hospitals of several 
local universities, following normal or caeserian term deliveries, in accordance with 
ethical standards of the local ethical committee of Yeditepe University Hospital. A 
bag system containing anticoagulant within the collection bag was used. 
2.1.2 Solutions and culture media 
2.1.2.1 Isolation solutions for MSCs 
RosetteSep
®
 Human Mesenchymal Stem Cell Enrichment Cocktail (Stem Cell 
Technologies, Vancouver, Canada) contains combinations of mouse and rat 
monoclonal antibodies that are bound in bispecific tetrameric antibody complexes 
which were raised against cell surface antigens on hematopoietic stem cells (CD3, 
CD14, CD19, CD38, CD66b) and glycophrin A on red blood cells. Due to 
crosslinking with the undesired cells, it enriches MSCs.  
Hanks’ Balanced Salt Solution (HBSS) (Gibco, Grand Island, New York, USA) was 
used to dilute the blood sample (Table 2.1). 
Ficoll-Paque (TM) Plus (Stem Cell Technologies, Vancouver, Canada) was used for 
density gradient centrifugation to isolate mononuclear cells from UCB.  
Phosphate-buffered solution (PBS) (Gibco, Paisley, Scotland, UK) was also used in 
isolation process to wash out cells during centrifugation steps.  
 
 
 
24 
Table 2.1 : Components of HBSS (Url-4). 
Inorganic Salts mg/L 
Calcium Chloride.2H2O 140 
Magnesium Sulfate 
(anhydrous) 
100 
Potassium Chloride 400 
Potassium Phosphate 
Monobasic (anhydrous) 
60 
Sodium Chloride 8000 
Sodium Phosphate Dibasic 
(anhydrous) 
48 
Others mg/L 
D-Glucose 1000 
Sodium Bicarbonate 350 
2.1.2.2 Culture media for MSCs 
MesenCult
®
 MSC Basal Medium (Human) containing Mesenchymal Stem Cell 
Stimulatory Supplements (Stem Cell Technologies, Vancouver, Canada) was used 
for cultivation and expansion of MSCs. Basal Medium is based on McCoy’s Medium 
(Bieback et al., 2004). Table 2.2 shows the components of McCoy’s Medium.   
As a second medium for cultivation of MSCs, Dulbecco’s modified Eagle’s medium 
(DMEM)-low glucose (Biochrom AG, Berlin, Germany) supplemented with 20% 
Fetal Bovine Serum (FBS) (Gibco, Canada, USA) with 1% L-glutamine (Gibco, 
Paisley, Scotland, UK) was used and named as Standard Medium.  
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Figure 2.1 : Components of McCoy’s Medium (Url-5). 
2.1.2.3 Culture media for ECs 
EndoCult
®
 Liquid Medium Kit (Stem Cell Technology, Vancouver, Canada) 
containing EndoCult
® 
Basal Medium with 10% EndoCult
®
 Supplement is needed for 
the growth of ECs.  
 
DMEM-low glucose (Biochrom AG, Berlin, Germany) supplemented with 20% FBS 
(Gibco, Canada, USA) and 1% L-glutamine (Gibco, Paisley, Scotland, UK) was also 
used as a second medium for the cultivation of ECs.   
2.1.3 Antibodies 
2.1.3.1 Antibodies for MSCs 
To characterize the phenotype of some cell surface antibodies against human 
antigens including CD133-PE  (phycoerythrin-conjugated), CD44-FITC (fluorescein 
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isothiocyanateconjugated) (eBioscience, San Diego, USA), CD73-PE (Biolegend, 
San Diego, USA), CD90/Thy-1-FITC, CD105/SH2-PE, CD34-PE and CD45-FITC 
(Beckman Coulter, Marseille, France) were used. 
2.1.3.2 Antibodies for ECs 
Selected antibodies including VCAM-1/CD106-PE (eBioscience, San Diego, USA), 
VE-Cadherin/CD144, and CD309/KDR/VEGFR2 (Beckman Coulter, Marseille, 
France) were used to verify MSC differentiation into EC.   
2.1.4 Dyes 
Trypan Blue (Invitrogen, Grand Island, New York, USA) was used for counting 
viable cells. 
2.1.5 Chemicals 
Trypsin-EDTA (Ethylenediaminetetraacetic acid) (Gibco, Canada, USA) was used in 
the subcultivation process to detach cells from cell culture flasks. 
PDMS (Sylgard 184; Dow Corning Corp., MI, USA) was used for the production of 
scaffold material.  
SU-8 3050 (MicroChem Corp., MA, USA) was used as a curing agent for PDMS 
production.  
Vybrant
®
 MTT Cell Proliferation Assay Kit (Life Technologies, Leiden, 
Netherlands) was used for determination of cell number and viability using standard 
microplate absorbance reader.  
Ethanol (Merck Millipore, Darmstadt, Germany) and Isopropanol (2-propanol) 
(Merck Millipore, Darmstadt, Germany) were used for sterilization of PDMS 
samples.   
DMSO (dimethyl sulfoxide) (Sigma-Aldrich, Saint Louis, USA) was used during the 
cell proliferation and viability assay. 
2.1.6 Growth factors 
Differentiation of UCB-derived MSCs into ECs was performed by VEGF from 
mouse and human (Millipore, Darmstadt, Germany). 10 μg lyophilized VEGF was 
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diluted with 4 mL of sterilized water and aliquoted as 150 μL, so each tube of 150 μL 
contained 375 ng VEGF to be stored. 
2.1.7 Laboratory Equipment 
Laboratory equipments used in the study were shown in Table 2.3. 
Table 2.2 : Laboratory equipment. 
Flow cytometry Beckman Coulter, USA 
Pipettes Eppendorf, USA 
Microscope 
Olympus IX71, USA 
Zeiss Discovery V20 Stereo Microscope, 
Germany 
Incubator 
Thermo electron corporation Hera cell 240, 
USA 
Laminar air flow cabinet Hera safe KS12, USA 
Centrifuge Beckman Coulter, USA 
Water distillation system Millipore, USA 
Deep freezer Arcelik 2021D, Turkey 
Refrigerator Arcelik 1061M, Turkey 
Owen  
Spin coater Laurell Technologies Corporation, USA 
Hotplate Präzitherm-Harry gestigkeit GMBH, Germany 
Microplate reader Bio-Rad, USA 
Photolithography 
machine 
OAI Hybralign Series 200 
Photo plotter OAI Mask Aligner, USA 
Goniometer DataPhysics Instruments GmbH, Germany 
Autoclave Nuve, Turkey 
Stretcher and clamps Homemade 
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2.2 Methods 
2.2.1 Collection of UCB samples 
UCB units were collected from women who gave birth in hospitals of several local 
universities and obtained following normal or caeserian term deliveries, in 
accordance with ethical standards of the local ethical committee. Sample bags 
containing 28 mL of citrate phosphate dextrose (CPD) anticoagulant were used for 
the collection of UCB samples. 
The samples were processed within 24 hrs due to the rapid decrease in cell viability 
and activity. The units were stored at 22±4oC before processing. 
2.2.2 Collection of native vessel samples 
Native vessel samples were kindly provided by the Department of Urology in the 
Istanbul University-Cerrahpasa Medical Faculty. Samples were stored in PBS 
solution containing antibiotics and antimycotics at 4
o
C until use. 
2.2.3 Isolation of MSCs from UCB 
4 mL of blood samples were taken into 15 mL falcon tubes, followed by the addition 
of 50 μL RosetteSep® Human Mesenchymal Stem Cell Enrichment Cocktail per mL 
of blood sample. Tubes were then incubated for 20 minutes at room temperature to 
eliminate undesired cell types including red blood cells (Figure 2.2). 
 
Figure 2.2 : Crosslinking of unwanted cells to red blood cells (Url-6). 
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RosetteSep
® 
crosslinked unwanted cells to red blood cells, thus forming 
immunorosettes as seen in Figure 2.1. Following the centrifugal removal of the 
immunorosettes, highly purified target cells between the plasma and the density 
gradient medium were collected. Then, HBSS was added to each tube in a ratio of 
1:1 and gently mixed. The diluted sample was layered onto 6 mL of Ficoll-Paque
®
 
slowly (to prevent the mixing of Ficoll and blood sample) and centrifuged for 25 
minutes at 1800 RPM at room temperature. After centrifugation, plasma fraction was 
removed and cells which took a shape of a colloidal ring in the tube were gently 
transferred to fresh 15 mL tubes. After washing cells with PBS or HBSS they were 
centrifuged at 1800 RPM for 5 minutes at room temperature. Following supernatant 
removal, cell pellet was observed (Figure 2.3). 
 
Figure 2.3 : Isolation of MSCs (Url-7). 
2.2.4 Mononuclear cell counting 
After separation with Ficoll-Paque
® 
and obtaining
 cell pellet, 10 µL of sample was 
used for cell counting and to observe their viability. Mononuclear cells were stained 
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via Trypan Blue (Fan et al., 2009). While unstained cells were alive, stained cells 
were dead. The calculation for viability was done with the following formula;  
Viability (%) = Alive cell / Total cell x 100 
2.2.5 Culture and expansion conditions of UCB-derived MSCs 
Optimization of cultivation conditions was done with two different media. After 
obtaining the pellet, cells were resuspended in 2 mL of cultivation medium which 
was composed of MesenCult
®
 MSC Basal Medium (Human) containing 10% 
Mesenchymal Stem Cell Stimulatory Supplements and or in Standard Medium 
containing DMEM-low glucose supplemented with 20% FBS and 1% L-glutamine. 
Roughly 2x10
6 
cells were seeded in filter-capped T-25cm
2 
flasks having 5 mL of 
medium.  
Cells were cultivated in an incubator containing 5% CO2 at 37
o
C. The first medium 
replacement was done within 3 days using MesenCult
®
 medium and daily for 
Standard Medium thereafter, to remove non-adherent red blood cells. Following 14 
days of cultivation and reaching 70% confluency, a subcultivation was done. 
Medium was removed and the cells were washed twice with PBS. 2 mL trypsin-
EDTA was then added and the flask was kept inside the incubator for 5 minutes. 
Then, 2 mL of fresh medium was added to collect the detached cells. After that, cells 
were transferred into a fresh falcon tube and centrifuged at 1800 RPM for 5 minutes. 
Supernatant was discarded again and cells were resuspended with Standard Medium 
or MesenCult
®
 MSC medium and reseeded at 2x10
6
 cells per flasks and named as 
passage 1 (P1) cells. 
2.2.6 Immune phenotypic analysis of UCB-derived MSCs 
Although there are no specific cell surface markers for characterization of MSCs, it 
was observed that different laboratories have chosen wide range of antibodies for 
characterization.  
In the study, antibodies against human antigens including CD133 (Oswald et al., 
2004; Kern et al., 2006), CD73/SH3 (Bieback et al., 2004; Oswald et al., 2004; Lee 
et al., 2005; Kadivar et al., 2006; Chamberlain et al., 2007), CD90/Thy-1 (Bieback et 
al., 2004; Oswald et al., 2004; Kern et al., 2006; Chamberlain et al., 2007), 
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CD105/SH2 (Bieback et al., 2004; Oswald et al., 2004; Chamberlain et al., 2007; 
Jazayeri et al., 2008), CD34, CD44, CD45 (Pountos et al., 2007) were used for the 
characterization. Because anti-CD45, anti-CD34 and anti-CD133 are typical 
hematopoietic lineage markers (Gilmore et al., 2000; Kim et al., 2004), they were 
used as control markers in the study.  
For immune phenotypic analyses, 100 µL of samples was incubated with 20 µL of 
isotypic solution for control tube and with 20 µL of each antibody for test tubes for 
15 minutes at room temperature in the dark. Then, 250 µL of PBS was added to each 
tube and centrifuged at 1800 RPM for 10 minutes. After centrifugation, supernatant 
was discarded without disturbing the pellet. Finally, 250 µL of fresh PBS was added 
to each tube, vortexed and then analyzed by flow cytometry. 
2.2.7 Endothelial differentiation of UCB-derived MSCs 
A small-scaled experiment was designed to show the best VEGF ratio. Freshly 
isolated MSCs were cultured in EndoCult
®
 Basal Medium with 10% EndoCult
® 
Supplement including 40, 45, 50, 55 or 60 ng/mL VEGF, respectively (Figure 2.4). 
These cells were incubated at 37
o
C for 13 days. Medium was replaced every 2 days. 
 
Figure 2.4 : A small-scale experiment containing different VEGF ratios. 
For endothelial differentiation, cells from passage 5 that were grown in Standard 
Medium were seeded as three-well clusters in DMEM-low glucose containing 20% 
FBS and refreshed every 2 days for 7 days. Cells that received only DMEM and 20% 
FBS was the control group, and the two well contained DMEM+20%FBS with 50 
ng/mL and 55 ng/mL VEGF, respectively (Figure 2.5). The medium was replaced 
every 2 days. 
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Figure 2.5 : Endothelial differentiation with two different VEGF ratios (Control 
group, 50 ng/mL and 55 ng/mL VEGF). 
2.2.8 Isolation of ECs from native vessels 
Native vessel samples were digested mechanically and then treated with collagenase 
enzyme (0,5 mg/mL) for 1 hr at 37
o
C. Undigested blocks were removed by using a 
cell strainer and isolated ECs were washed with PBS for 10 minutes at 1200 RPM to 
be cultivated in DMEM-low glucose supplemented with 30% FBS and 1% L-
glutamine. 
Furthermore, undigested blocks were treated with collagenase enzyme (0,5 mg/mL) 
overnight to optimize the isolation condition for ECs. 
2.2.9 Immune phenotypic analysis of ECs 
Expression of specific endothelial antibodies against human antigens including 
VCAM-1, KDR/VEGFR2 (Oswald et al., 2004; Jazayeri et al., 2008) and 
VECadherin/CD144 (Oswald et al., 2004; Kern et al., 2006) were monitored by flow 
cytometry to verify endothelial differentiation. 20 μL of the antibodies listed above 
was added to ~2x10
5
 cells. Cells were incubated with the antibody for 15 minutes at 
room temperature in the dark. Then, 250 µL of PBS was added to each tube and 
centrifuged at 1800 RPM for 10 minutes. After centrifugation, supernatant was 
discarded without damaging the pellet. Finally, 250 µL of fresh PBS was added to 
each tube, vortexed and were analyzed using flow cytometry. 
2.2.10 Design and fabrication of PDMS 
Different geometric designs were performed using L-EDIT (Tanner Tools, USA). 
They were printed on transparent films at a resolution of 10000 dpi using a photo 
plotter and used as masks in contact photolithography to make master templates. 
Microfabrication techniques outlined in Figure 2.6 were used to create the master 
template starting with the deposition of negative photoresist (SU-8 3050) on a four-
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inch silicon wafer using a standard spin coater. The production of master template 
was outlined as follows: 
a- The clean wafer was put on the spinner vacuum chuck. 
b- About 3 ml of SU-8 3050 was poured on the center of the wafer avoiding 
trapping bubbles in the resist.  
c- The photoresist was spin coated to get 50 m thickness. 
d- The wafer was placed on a flat surface at room temperature for 5 minutes. 
e- The wafer was placed in 65oC oven for 5 min, then it was taken to 95oC hot 
plate for 15 min, and finally it was transferred to the 65
o
C oven for 5 min. 
f- The photoresist was allowed to relax at room temperature for 10 min. 
g- The photoresist was exposed to UV light in vacuum contact mode. Exposure 
time was about 8 sec to get 50 m thickness. 
h- The wafer was then taken out and the mask was removed. 
i- The wafer was put for 1 min to 65oC oven, then it was transferred to 95oC hot 
plate for 5 min.  
j- The photoresist was allowed to relax at room temperature for 10 min. 
k- The wafer was placed in the developer  for 5-10 min, submerged in isopropyl 
alcohol and then placed in deionized water for 2-3 min. 
l- The wafer was gently dried using dry N2. 
m- The wafer was then put in 150oC oven for 2-3 hours. After that, the patterns 
on the wafer were inspected under a microscope. 
For the production of PDMS membranes, the spinning rate was regulated to achieve 
the desired thickness (50 µm) at 3000 RPM for 30 seconds with acceleration of 300 
RPM/second. Two stage continuous process was used. At the 1st stage, 500 RPM for 
10 sec. with acceleration of 110 RPM/sec; at the 2nd stage 3000 RPM for 30 sec. 
with acceleration of 330 RPM/sec.  were used. The master was formed with a resist 
pattern that had a thickness of approximately 50 µm. For the replica molding, an 
instant barrier surrounding the master silicone wafer was made of aluminium foil. 
Then, PDMS was cast over the SU-8 master (Park et al., 2009). Air bubbles were 
removed from the PDMS mixture using a degassing chamber, and the clear PDMS 
was cured on a hotplate at 75
o
C for at least 24 hours. After curing, the PDMS replica 
was removed from the master wafer. PDMS was then sterilized with isopropyl 
alcohol and DI water. 
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Figure 2.6 : Microfabrication procedure. (A) Spin-coating of the negative 
photoresist was done onto a silicon wafer which was then exposed to UV 
irradiation through patterned photomask. (B) Unpolymerized photoresist 
was removed. PDMS was poured on the patterned silicon wafer and spun 
to desired thickness, degassed, cured at 75°C, and resulted in a 
micropatterned membrane. PDMS membrane was then removed from the 
wafer. 
PDMS surfaces were designed as geometric patterns of straight-lines, cross-shapes, 
circular shapes or square/diamond shapes. Dimensions of these structures and the 
distance between each structure were varied as shown in Figure 2.7. 
 
 
 
Figure 2.7 : Designs of PDMS pattern formations  (P = cross-shaped, C = circular-
shaped, L = straight-lines, S = square/diamond-shaped patterns). 
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Figure 2.8 : Designs of cross-shaped PDMS patterns produced after getting the 
first experimental results (P = cross-shaped patterns). 
After getting results with different patterned PDMS samples, new designs with cross-
shaped PDMS samples were produced and tested for their effects on cell 
proliferation and viability (Figure 2.8 and Figure 2.9). 
 
 
Figure 2.9 : Designs of PDMS pattern formations produced after getting the first  
experimental results (C=circular-shaped, S=square/diamond-shaped, 
L=straight-lines). 
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2.2.11 Plating and culturing of ECs on PDMS substrates 
PDMS substrates were cleaned in 70% ethanol and then DI (deionized) water for 20 
minutes each. The substrate was then dried in an oven and stored submerged in DI 
water until ready for plating cells.  
Cleaned PDMS substrates were placed in 6-well petri dishes. Approximately 10
5
 
cells per well were suspended in the middle of the substrate and incubated for 60 s. 
Then, the cells were incubated at 37
o
C with 95% humidity and 5% CO2. 
2.2.12 Cell proliferation and viability analysis 
After the sterilization of PDMS materials, ECs differentiated from UCB-derived 
MSCs were used to test the effect of these scaffolds on cell proliferation and 
viability.  
Cells were platted at a density of 10
5
 cells per well. After 72 hrs of incubation in the 
presence of the tested scaffolds, cells were evaluated by the MTT assay, based on the 
reduction of tetrazolium salt to formazan crystals by dehydrogenase present in living 
cell mitochondria (Pinto et al., 2010). The formazan salt formation was directly 
related to the amount of dehydrogenase, providing an indirect measurement of cell 
proliferation.  
12 mM MTT stock solution was prepared by adding 1 mL of sterile PBS to one 5 mg 
vial of MTT (Component A). It was mixed by vortexing until dissolved. 
 After 72 hrs of cultivation with scaffolds, the medium was removed and replaced 
with 500 µL of fresh culture medium. 50 µL of the 12 mM MTT stock solution 
(prepared before) was added to each well. One negative control of 50 µL of the MTT 
stock solution was added to 500 µL of medium alone. Because of having 105 cells 
per well, the incubation time was shortened to 2 hours at 37
o
C.  After labelling the 
cells with MTT, 425 µL of medium was removed from the wells. 250 µL of DMSO 
(Sigma-Aldrich, USA) was added to each well and mixed throughly with the pipette. 
They were incubated for 10 minutes at 37
o
C. Each sample was then mixed and 
optical density was measured at 570 nm. 
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2.2.13 Stress induced rolling membrane (SIRM) technique 
In this technique, two elastic PDMS membranes were bonded for the fabrication of 
SIRM.. According to the technique, the top membrane was a piece of cured PDMS 
and it was stretched to manually produce stress (Figure 2.10). The bottom membrane 
was semicured PDMS membrane and it was relaxed. 
 
Figure 2.10 : SIRM technique. 
The top layer membrane was fabricated with different patterned samples. To 
accomplish this, PDMS was poured onto the wafer that have different patterns. The 
production of the top layer via spin-coating was done at 300 RPM for 60 s to get 100 
µm thickness. After spin-coating, it was baked at 80oC for 15 minutes. Then, the 
bottom layer was produced by pouring PDMS onto a non-patterned wafer. The 
production of the bottom layer via spin-coating was done at 300 RPM for 60 s as 
well as in the production of top layer. The bottom membrane was baked at 80
o
C for 5 
minutes. Then, the top layer was stretched onto the bottom membrane by a stretcher 
to produce stress (Figure 2.11).   
 
   
Figure 2.11 : The top membrane was produced manually (before SIRM technique). 
The two ends of PDMS membrane were fixed by two clips. After adhesion of the 
two layers, they were baked for curing and adhesion at 80
o
C for 30 minutes. After 
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overnight incubation at room temperature, two layers were peeled off and fixed on 
the surface of a petri dish by a commercial tape (Figure 2.12). 
      
Figure 2.12 : The stress was produced by a stretcher. 
2.2.14 Optimization of SIRM technique 
The size of the tubes and the wall thickness were verified before culturing cells with 
different patterned samples. The radius of curvature of the inner tube was assessed 
by changing the tensile elongation. 
2.2.15 Rolling the tubes 
After fixation of the membranes on the surface of a petri dish by a commercial tape, 
the membranes were sterilized with isopropanol and distilled water for the 
preparation of cell cultivation. Then, one end of the SIRM was cut to release the end 
to roll up. During the rolling process, whole membrane was inside the petri dish 
containing culture medium. In the petri dish, the rolling process was very slow that 
can be an advantage for less damage to the culture cells. 
2.2.16 Optimization of sterilization 
Cross-shaped PDMS samples were processed by three sterilization procedures 
normally used for biomedical devices: (a) steam autoclave - samples were placed 
inside an autoclave system at 121
o
C for 15 minutes; (b) ultraviolet light (UV) - 
samples were irradiated with UV light (254 nm, 100μW/cm2 for 30 minutes) inside a 
laboratory hood (~50 cm from light source); and (c) ethanol - samples were 
immersed in 70% ethanol for 30 minutes and dried in air at room temperature. All 
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samples were stored at room temperature for at least 24 hrs before microscopic 
analysis. The effects of sterilization were analyzed using light microscope. 
2.2.17 Microscopic analysis of PDMS samples 
MSC and EC morphologies were observed using an Olympus IX-71 Inverted 
Microscope. PDMS samples with various patterns were studied under a Zeiss 
Discovery V20 Stereo Microscope. 
2.2.18 Contact angle analysis of PDMS samples 
Goniometry was used to measure the surface contact angles of the various PDMS 
substrates. This technique provides information on surface hydrophilicity, by 
assessing the material’s wetting characteristics (Wang et al., 2010). Surface 
wettability with water was measured in triplicate with the ‘contact angle system 
OCA’ (DataPhysics Instruments GmbH, Germany) on three different locations of the 
PDMS substrate. A 2 μL droplet of DI water was placed on the substrate surface and 
the static contact angle was measured immediately thereafter.  
 
 
 
 
40 
 
 
 
 
 
 
 
 
41 
 
3.  RESULTS 
3.1 Isolation and Cultivation of MSCs from UCB 
The UCB mononuclear cells were isolated by gradient density centrifugation with 
Ficoll-paque. Culture showed heterogeneity during the first 4 days. At the bottom of 
culture flasks, the spindle-shaped cells appeared. Round cells were suspended in the 
medium but throughout the medium refreshments, their number gradually decreased. 
UCB-derived MSCs grew as a confluent monolayer with cobblestone morphology.  
Mesenchymal cells were long and thin. They were widely dispersed and some 
reticular fibrils were observed around the small cell body. Most of the cells that 
attached to the plastic surface showed a fibroblast-like spindle shape. Then, they 
started to proliferate to form a uniform confluent cell monolayer (Figure 3.1). 
Cultured cells reached confluency in 14 days. 
 
Figure 3.1 : Fibroblastoid and adherent UCB-MSCs (x20, 22nd day). 
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MesenCult
®
 commercial growth medium was used for expansion. All the cultivation 
was conducted in GMP conditions; therefore, no antibiotics solutions was added. 
Medium was refreshed regularly without detaching the cells.   
During subcultivation processes, cells that grew in MesenCult
®
 medium were 
harvested with a cell scraper. This created a significant sheer stress and caused,  cell 
damage, therefore, harvesting procedure and culture conditions were changed.  
Instead of MesenCult
®
 medium, Standard Medium was used for the cultivation. 
Trypsin-EDTA was used to recover the cells from the flask surface instead of cell 
scraper.  As a result, MSCs were able to grow through 7 subcultures without losing 
viability. Morphological analysis of cells incubated in Standard Medium was shown 
in Figure 3.2. 
 
Figure 3.2 : Morphology of MSCs cultured in Standard Medium showed 
fibroblastoid and adherent morphology (x20, passage 1). 
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3.2 Immune Phenotypic Analysis of MSCs 
At present, a well-defined criteria is not known for the characterization of MSCs, 
since, there is not a specific-single marker to delineate in vivo MSCs. On the other 
hand, positive and negative phenotypic staining are widely used for diagnostic 
purpose. For example, MSCs express various surface markers, such as anti-CD13, 
anti-CD44, anti-CD54, anti-CD55, anti-CD90, anti-CD105. They do not express 
anti-CD31, anti-CD34, anti-CD45, anti-CD11a, anti-CD11c, anti-CD80.  
In our study, we utilized anti-CD34-PE, anti-CD45-FITC, anti-CD90-FITC and anti-
CD44-FITC markers (Figure 3.3). 72.9% of cells showed negative expression for 
both anti-CD34 and anti-CD45, which is also a characteristic of MSCs. 46.5% of the 
cells from P(5) showed positive expression for MSC marker anti-CD90. 41.8% of the 
cells from P(5) showed positive expression for MSC marker anti-CD44. 
When MSCs from P(6) and P(7) were compared, it was widely observed that 
expression of surface antigens declined. Figure 3.4. shows the comparison of 
expression profiles of cells from P(5), P(6) and P(7). In addition to the expression 
differences, when their growth capacities were compared, it was seen that cells from 
P(6) reached confluency in 2 weeks while cells from P(1) to P(5) had reached 70% 
confluency in 7 days. MSCs from P(7) were unable to reach 70% confluency on the 
flask surface in more than 20 days.  
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Figure 2.13 :  
Figure 2.14 :  
Figure 2.15 :  
Figure 2.16 :  
Figure 2.17 :  
Figure 2.18 :  
 
Figure 3.3 : Expression profiles of cell surface markers on MSCs. (a) anti-CD34/45; (b) anti-CD90; (c) anti-CD44.  
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Figure 3.4 : Distribution of expression profiles for different passages.  
3.3 Endothelial Differentiation with VEGF 
In the study, VEGF was used for in vitro endothelial differentiation. A small-scale 
experiment was designed to determine whether differentiation would be successful or 
not (Figure 3.5).  
 
Figure 3.5 : Small-scale experiment to show the effect of different concentrations of 
VEGF. Control group, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL and 60 
ng/mL, respectively. 
 
Mononuclear cells isolated from UCB were cultured in six-well culture plates 
(Figure 3.5). Control group contained only EndoCult
®
 medium and the other five-
wells received various concentrations of VEGF. Medium refreshments were done in 
every 2 days. 
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As shown in the following figures, on the fifth day of culturing, outgrowing of the 
cells formed the cobblestone morphology (circular shape) which was different from 
MSCs’ fibroblastoid structure (Figure 3.6).  On the thirteenth day of culturing, not 
only five-wells but also control group showed cobblestone morphology (Figure 3.7).  
When the concentrations of VEGF were compared, application of 50 ng/mL and 55 
ng/mL VEGF provided more efficient cellular differentiation in five days of 
culturing.  
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Figure 3.6 : Growth in the presence of various VEGF concentrations on the 5th day of culturing. (C is the control group without VEGF). 
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Figure 3.7 : Growth in the presence of various VEGF concentrations on the 13th day of culturing. (C is the control group without VEGF).
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3.4 Immune Phenotypic Analyses of Differentiated ECs cultured with 
EndoCult-Kit
®
 
Following thirteen days of incubation, cells were harvested to analyze the expression 
of surface antigens, including anti-CD144 (VE-Cadherin), anti-CD106 (VCAM-1), 
anti-CD309 (VEGFR-2/KDR) and anti-CD44 (Figure 3.8). 
 
Figure 3.8 : Distribution of expression profiles of samples cultured with 
EndoCult-Kit
®
 
As shown in Figure 3.8, differentiation ratio of the cells were not as high as 
expected. When VEGF concentrations were varied, flow cytometry analysis showed 
promising results with 50 and 55ng/mL VEGF. 
3.5 Immune Phenotypic Analyses of Differentiated ECs cultured with Standard 
Medium 
Endothelial differentiation was also observed after culturing cells in Standard 
Medium. MSCs from P(5) were cultured for seven days in Standard Medium 
containing DMEM and 20% FBS by addition of 50 ng/mL or 55 ng/mL VEGF. 
Expression levels of some antibodies such as CD144 (VE-Cadherin), CD309 
(VEGFR-2/KDR), CD44, CD73, CD90, CD105, CD34, CD45, CD133 were 
analyzed. While cells cultured in the presence of 50 ng/mL VEGF showed higher 
expressions for endothelial markers, those cultured in the presence of 55 ng/mL 
50 
showed lower expressions for stem cell markers, such as CD34/45 and CD90/105 
(Figure 3.9). 
 
 
Figure 3.9 : Distribution of expression profiles of samples cultured with 
Standard Medium. 
3.6 Comparison of Immune Phenotypic Analysis of Differentiated and Native 
Vessel-derived ECs 
ECs isolated from native vessels were compared with UCB-MSC derived ECs 
produced in the presence of 50 and 55 ng/mL of VEGF (Figure 3.10). 
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Figure 3.10 : Histogram results of native vessel-derived ECs and UCB-differentiated 
ECs. X-axis is the intensity of the fluorescence, where Y- axis shows 
the cell number. Percentages give information about the percent of the 
cells that expressed markers positively. 
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Figure 3.10 (continued) : Histogram results of native vessel-derived ECs and UCB-
differentiated ECs. X-axis is the intensity of the fluorescence, where 
Y-axis shows the cell number. Percentages give information about 
the ratio of the cells that expressed markers. 
 
 
As seen in Figure 3.10, although cell number was low, differentiation occurred 
successfully. While there was no significant difference in the results between 
cultures contained 50 ng/mL or 55 ng/mL VEGF, according to our previous results, 
cells cultured with 50 ng/mL VEGF concentration showed higher expression for 
endothelial markers and lower expression for MSC markers. Besides, microscopic 
analysis revealed that there were still undifferentiated MSCs in the culture. 
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Therefore, addition of VEGF to the culture medium was extended for another 10 
days. Differentiation was analyzed via flow cytometry with endothelial markers 
including anti-CD144, anti-CD106 and anti-CD309. The results were compared with 
ECs isolated from native vessel treated with collagenase for 1 hr or 24 hrs before 
cultivation (Figure 3.11). 
 
 
Figure 3.11 : Comparison of endothelial markers for UCB-MSC derived ECs and 
native vessel-derived ECs. X axis: fluorescence intensity; Y-axis: cell 
number. 
 
For the native vessel EC isolation, comparison of incubation periods with 
collagenase revealed that the sample treated with the enzyme for 24 hrs produced 
higher expression for endothelial markers. Moreover, their growth capabilities were 
different. For example, while 24 hrs-enzyme-treated cells reached confluency in a 
week, 1 hr-treated cells reached confluency in two weeks.  
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On the other hand, culturing of MSCs in the presence of VEGF for longer periods 
revealed that during longer cultivation, most of the UCB-derived MSCs 
differentiated into ECs and showed higher expression of anti-CD144, anti-CD106 
and anti-CD309 (Figure 3.11). 
3.7 Design of PDMS Patterns 
In the study, PDMS surfaces were designed as geometric patterns of straight lines, 
cross-shapes, circular shapes or square/diamond shapes to investigate their possible 
effects on cell viability and proliferation. Dimensions of these structures and the 
distance between each structure were varied as shown. The optical microscope 
images of different PDMS designs were illustrated in Figure 3.12. 
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Figure 3.12 : Optical microscopic images of patterned PDMS samples. (A) P50; (B) C50; (C) S50; (D) L50; (E) P100; (F) C100; (G) S100; 
(H) L100.
56 
ECs differentiated from UCB-MSCs were cultured on PDMS scaffolds with the 
different geometric shapes. When these geometric shapes on scaffolds were 
compared, it revealed that “cross-shaped” (P50 and P100) structure provided high 
cell viability and proliferation (Figure 3.13).  
 
Figure 3.13 : Cell viability and proliferation of ECs on PDMS 
scaffolds (P = cross-shaped, C = circular-shaped, L = straight-lines, 
S = square/diamond-shaped patterns). 
 
3.8 Production of Different Designs of Cross-shaped PDMS Membranes 
Since, ‘cross-shaped’ PDMS surfaces showed higher cell proliferation and viability,  
different patterns of these scaffolds such as P80, P120 and P150 were produced 
(Figure 3.14). MTT analysis was applied to all designed surfaces and their effects on 
cell proliferation and viability were tested. 
The analysis revealed again that P100 showed the highest cell viability/proliferation 
capacity (Figure 3.15). 
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Figure 3.14 : Optical microscopic images of patterned PDMS samples (A) P50; 
(B) P80; (C) P100; (D) P120; (E) P150. 
 
 
 
 
 
Figure 3.15 : Cell viability and proliferation of ECs on newly designed PDMS 
scaffolds (P = cross-shaped, C = circular-shaped, L = straight-
lines, S = square/diamond-shaped patterns). 
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3.9 SIRM Technique 
In this experiment, two different PDMS membranes were used, i.e., a streched 
PDMS membrane and a semicured PDMS membrane. Manual elongation provided 
about 1.5 centimeter increase in height.  
Table 3.1 and Figure 3.16 showed effect of the elongation in height. When they were 
compared, c sample appeared to have smaller inner diameter (Figure 3.16). 
 
Table 3.1 : The quantity of the elongation after manual production of PDMS 
membranes. 
 
Samples  Before 
elongation 
(cm) 
After 
elongation 
(cm) 
a width 5,5 5,5 
 height 5 6,5 
b width 2 2 
 height 3 4,5 
c width 1,5 1,5 
 height 5 7 
 
 
  
                   (a)                                                 (b)                                   (c) 
Figure 3.16 : After rolling of the PDMS membranes. 
 
In the  PDMS membranes, the thickness of the samples was analyzed after rolling 
procedure. The thickness of the samples was approximately 124 m (Figure 3.17). 
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Figure 3.17 : Thickness of the rolled PDMS sample produced by manually 
 elongation. 
 
As a second experiment, in order to increase the elongation of the membranes, a 
stretcher was used to produce stress instead of manual stretching. The two ends of 
PDMS membranes were fixed by clips. Therefore, position of clips and fixation of 
membranes could be controlled by the holey substrate. It provided 3 centimeter 
increase in height. This allowed to produce an inner diameter smaller than other 
membranes (Table 3.2, Figure 3.18). 
 
Table 3.2 : Elongation by a stretcher following the production of PDMS membranes. 
 
  
Before 
elongation 
(cm) 
After elongation 
(cm) 
Sample width 5,3 5,3 
 height 7 10 
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Figure 3.18 : PDMS membrane was produced by a stretcher. Internal radius: 1 mm. 
 
The thickness of the rolled PDMS samples was calculated as about 130 m (Figure 
3.19). 
 
 
Figure 3.19 : Thickness of the rolled PDMS sample produced by a stretcher. 
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3.10 Optimization of the SIRM Technique 
The thickness of the membrane and the relative elongation (tensile strain) were 
determined. The radius of curvature of the inner tube was quantified by the tensile 
elongation (Figure 3.20). According to the experiment, when the thickness was 
increased, the radius increased (Table 3.3). Because, the larger elongation induces 
larger stres. Therefore, while the tensile elongation increased, the radius decreased. 
 
Figure 3.20 : Relationship between tensile elongation and the radius.   
(IR; innermost round) 
 
 
Table 3.3 : The radius of IR is related to tensile strain. 
 
IR (mm) Tensile Strain (%) 
4,7 11,1 
3 23 
3 24 
2 38 
1 42 
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3.11 PDMS Surfaces after SIRM Technique 
Comparison of different patterned PDMS substrates showed that cross-shaped 
designs provided higher cell proliferation and viability than did other designs. On the 
other hand, applying SIRM technique provided a large difference in the length of the 
structures and distances between each structure (Figure 3.21 and Figure 3.22). Table 
3.4 showed that SIRM technique provided about 100% increase in the lengths of the 
structures. 
 
Table 3.4 : Length of the structures after SIRM technique. 
 
Designs 
Before SIRM 
technique 
(dimension of the 
structure) 
After SIRM 
technique 
(dimension of the 
structure) 
P50 50 m 96 m 
P80 80 m 184 m 
P100 100 m 192 m 
P120 120 m 221 m 
P150 150 m 290 m  
C50 50 m 84 m 
C100 100 m 183 m 
S50 50 m 90 m 
S100 100 m 177 m 
L50 50 m 135 m 
L100 100 m 209 m 
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Figure 3.21 : Cross-shaped PDMS substrates after SIRM technique. (A) P50; (B) P80; (C) P100; (D) P120; (E) P150. 
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Figure 3.22 : Circular-shaped, square/diamond shaped and straight-linear shaped PDMS substrates after SIRM technique. 
(A) C50; (B) C100; (C) S50; (D) S100; (E) L50; (F) L100. 
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PDMS substrates designed in various surface structures with SIRM technique were 
analyzed for their effect on cell proliferation and viability. It was widely seen that 
after applying SIRM technique, P100 design still provided higher cell proliferation 
and viability (Figure 3.23). While cell proliferation between P50 and P80 were 
slightly different, difference between P120 and P150 were higher. C50 provided 
higher cell proliferation than did C100. On the other hand, square/diamond shaped 
(S50 and S100) and linear-lined (L50 and L100) PDMS substrates supported nearly 
the same level of cell proliferation and viability. 
 
 
Figure 3.23 : Cell viability and proliferation of ECs on PDMS scaffolds produced by     
SIRM technique.  
 
3.12 Optimization of Sterilization 
The surfaces of PDMS were examined using light microscope to determine how the 
patterned features might be affected by sterilization. Therefore, plus-shaped PDMS 
surface was chosen for the experiment. Examination of the post-sterilization 
specimens from cross-shaped PDMS formulation did not reveal any discernable 
pattern degradation or surface distortion.  
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3.13 Water Contact Angle Measurements 
The hydrophobicity properties of the various fabricated PDMS surfaces were 
characterized by the measurement of the water. 2 L of DI water droplets were 
placed on the fabricated surfaces. (Figure 3.24). Contact angle measurements were 
done at four different positions for each test sample. There was no statistically 
significant difference in contact angle among twelve different PDMS designs (Figure 
3.25). The results suggested that PDMS is a hydrophobic material, with a contact 
angle of  110 degrees. 
 
    
Figure 3.24 : Representative image of the water contact-angles on fabricated  
                              PDMS surfaces. 
 
 
 
Figure 3.25 : Contact angle (in degrees) of water on different PDMS substrates. 
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4.  DISCUSSION AND CONCLUSION 
In developed countries, cardiovascular diseases including arteriosclerosis, 
myocardial infarction, stroke, vascular diseases are still ranked among the top ten 
leading causes of mortality and morbidity (Williamson et al., 2006; Nemeno-
Guanzon et al., 2012). Although studies with new drugs and innovative devices have 
improved the quality of life for patients, they are still insufficient to reduce the 
mortality and morbidity rate (Zhang et al., 2007; Bourget et al., 2012). Besides, 
usage of various drugs for the treatment leads to autoimmune reactions and causes a 
variety of chemical reactions in the body. Thus, there is a strong demand for cell 
therapies and vascular grafts. Not only the high frequency of vascular diseases but 
also limited availability of surplus autologous blood vessels have led the usage of 
vascular tissue engineering approach (Nemeno-Guanzon et al., 2012; Abruzzo et al., 
2014). 
Vascular tissue engineering has been described as ‘an interdisciplinary field’ that 
restore, maintain and improve tissue function (Abruzzo et al., 2014; Li et al., 2014). 
The first tissue-engineered blood vessel was produced in 1986 by Weinberg and Bell 
(Ravi and Chaikof, 2010; Cleary et al., 2012). Vascular tissue engineering approach 
starts with the isolation of specific cells from the main cell source, their culture on a 
three-dimensional biocompatible scaffold under controlled environment, the delivery 
of the construct to the desired site and the direction of new tissue formation into the 
scaffold (Serbo and Gerecht, 2013).   
One of the limiting factors in vascular tissue engineering is the availability of 
suitable stem cell source (Kurpinski et al., 2006). MSCs are adult cells derived from 
the mesenchymal lineage tissues. They can be isolated from bone marrow, adipose 
and other tissues (Murphy et al., 2012). Previous studies have demonstrated that 
MSCs can be successfully used for tissue repairment and regeneration, such as 
myocardial infarction treatment (Kim et al., 2004; Kern et al., 2006; Williamson et 
al., 2006), spinal cord and bladder regeneration (Pountos et al.,2007; Bajada et al., 
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2008), osteogenesis imperfecta and severe idiopathic aplastic anemia (Manca et al., 
2008). 
Although bone marrow is the first and common source for MSCs, previous studies 
revealed that MSC-like cells could be isolated from UCB with phenotypic and 
differentiative potentials similar to those for bone marrow derived MSCs (Godara et 
al., 2008; Manca et al., 2008).  
In spite of initial reports, isolation of UCB-derived MSCs remained controversial 
because of inability of their isolation by other investigators. This could be resulted 
from two reasons, a-replication problems in MSC isolation because of their low 
numbers in UCB, b-the lack of unique phenotypic markers for their characterization 
(Manca et al., 2008; Fan et al., 2009). Despite these obstacles, UCB is a readily 
available and non-invasive source for MSCs. Therefore, we carried out the isolation 
and characterization of MSCs from UCB. 
MSCs can be isolated with different methods such as magnetic beads, density 
gradient centrifugation and flow cytometry (Godara et al., 2008). In the study, 
isolation was based on adherence to culture flasks as a key property of MSCs and 
density gradient centrifugation. Before density gradient centrifugation, RosettaSep
®
 
Human Mesenchymal Stem Cell Enrichment Cocktail was incubated with the sample 
to crosslink the undesired red blood cells. Nevertheless, removal of the red blood 
cells from the culture was inefficient since the product was designed for bone 
marrow. Therefore, during the isolation of MSCs, blood samples were only layered 
onto Ficoll-Paque (TM) Plus solution. 
In previous applications, UCB-derived MSCs were cultured with media such as low-
glucose DMEM or α-minimum essential medium (α-MEM) supplemented with L-
glutamine, penicillin, streptomycin and FBS or FCS (Wexler et al., 2003; Ju et al., 
2006; Schmidt et al., 2006; Liu et al., 2007; Meyer et al., 2008). In the current study, 
MesenCult
®
, a commercial medium, was used for the cultivation and expansion. 
During the experiments, penicillin or streptomycin was not added since all the 
cultivation was conducted in GMP conditions. When the cells grown in MesenCult
® 
 
reached confluency, they were subcultured with the help of a cell scraper. Since most 
of the cells were lysed and damaged with shear stress, Standard Medium and trypsin-
EDTA method was adopted for the cell detachment and subcultivation processes. 
With this modification, cells were able to grow through seven subcultures without 
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viability loss.  
Although there are no specific cell surface markers for MSCs, researchers have 
chosen different types of antibodies for characterization of MSCs. These cells 
generally express some surface proteins against human antigens at higher levels; 
such as CD55, CD105, CD90, SH4, matrix receptors CD44 (hyaluronate receptor, 
CD49b (alpha2-integrin), CD49d (alpha4-integrin), CD90, CD106 (vascular cell 
adhesion molecule [VCAM]-1); and another set of proteins usually in lower levels, 
such as CD14, CD31, CD34, CD45, CD133, CD62 or von Willebrand factor (vWF) 
and Flk-1 (Gilmore et al., 2000; Oswald et al., 2004; Pountos et al., 2007; Jazayeri et 
al., 2008). Here, four markers were studied to characterize UCB-derived MSCs. The 
flow cytometry analysis from passage 5 revealed that Standard Medium enhanced 
MSC growth and increased cell number. According to the results, 41.8% of cells 
from passage 5 expressed CD44, while 46.5% of cells were positive for CD90 and 
72.9% of the cells did not express the hematopoietic stem cells markers, CD34 or 
CD45. When the number of subcultivation was increased, a decrease in the 
expression of surface antigens and cell growth was observed.  
ECs are the gatekeepers between the blood components and bulk of the vessel wall. 
Their impairment is a leading cause for atherosclerosis and thrombosis (Naito et al., 
2011). Therefore, simple and efficient production of healthy ECs is a crucial step in 
vessel engineering.  
Researchers previously used various growth factors for differentiation of MSCs into 
ECs from sources like bone marrow. For instance, insulin like growth factor-1 (IGF-
1) with FBS or FCS was applied along with VEGF (Anderson and Hinds, 2011; 
Jazayeri et al., 2008). Liu et. al. used a growth medium containing different growth 
factors and VEGF (Liu et al., 2007). VEGF has a pivotal role for the in vitro 
differentiation of endothelial progenitor cells or stem cells into ECs, in vitro (Oswald 
et al., 2004). Oswald et al., designed an experiment about the optimum VEGF 
concentration. They cultivated the cells in the presence of two different 
concentrations of VEGF and once without VEGF. They investigated that when the 
cells were cultivated in the presence of 50 ng/mL VEGF, they showed a substantial 
level of capillary formation. In the current study, in vitro differentiation of UCB-
derived MSCs into ECs was provided as a useful model to show the effect of VEGF 
as the sole inducer on differentiation.  
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Not only microscopic analysis but also flow cytometry analyses were applied to 
investigate the endothelial phenotype. On the 13
th
 day of cultivation, cells were 
harvested to analyze for some of these markers. Anti-CD144 (VE-Cadherin), anti-
CD106 (VCAM-1), anti-CD309 (VEGFR-2/KDR) as well as anti-CD44 that is also 
expressed on ECs, were analysed. The results revealed that the rate of differentiaton 
was not as high as expected. Although control group did not contain growth factor, 
some surface markers were detected in higher quantities than the rest. This could be 
resulted from the usage of EndoCult
® 
Medium since it may already contain some 
growth factors inside. On the other hand, after flow cytometry analysis, similar to 
that reported in previous studies, 50 ng/mL, and 55 ng/mL VEGF application showed 
promising results (Oswald et al., 2004; Jazayeri et al., 2008). In another experiment, 
MSCs were cultured with Standard Medium to differentiate into endothelial-like 
cells with the presence of 50 ng/mL or 55 ng/mL VEGF. After seven days of 
culturing with VEGF, cells were analyzed by monitoring the expression levels of 
some endothelial markers against human antigens such as CD144 (VE-Cadherin), 
CD309 (VEGFR-2/KDR), MSC-positive markers such as CD44, CD73, CD90, 
CD105 and MSC-negative markers against human antigens such as CD34, CD45, 
CD133. Although cells treated with 50 ng/mL VEGF expressed the highest levels of 
endothelial markers such as anti-CD44, anti-CD309, they showed the lowest 
expression of anti-CD90, anti-CD105, anti-CD34, anti-CD45 which were all stem 
cell markers.  
Comparison of the characteristics of ECs differentiated from MSCs was also done 
with the native vessel-derived ECs. The results presented that some of the markers 
identifying MSCs were higher, when they were compared to the results from native 
vessel-derived endothelial cellss, which suggested there might be still MSCs that did 
not differentiate during cultivation with VEGF. Thus, when incubation period with 
VEGF was increased, most of the UCB-MSCs differentiated into endothelial-like 
cells and expressed unique endothelial markers in the highest level (~90%). When 
incubation time with the collagenase was compared, it was usually observed that 
samples treated with 24 hrs expressed higher endothelial markers rather than the ones 
treated for 1hr.  
Combining cells with an appropriate scaffold is of utmost importance in tissue 
engineering applications. The behavior of the engineered tissue is governed not only 
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by the physicochemical influences of the nearby environment but also by surface 
patterning and topography. Thus, more desirable cellular properties could be 
achieved by the incorporation of micro and nano-scale topographies (Kim et al., 
2013).
 
Lithography could be an efficient method for scaffold production in tissue 
engineering. Micropatterning of scaffold surfaces via lithography can influence 
various cell properties, such as morphology, proliferation or migration capabilities 
(Kurpinski et al., 2006; Anderson and Hinds, 2011). 
Since selection of correct scaffold structure is crucial for vessel reproduction, in 
previous studies PDMS was fabricated around different types of templates such as 
glass capillaries or nylon threads.
 
Some researchers reported data on attachment and 
proliferation of ECs in microfluidic PDMS channels, however, the importance of the 
surface roughness and structure was not evaluated sufficiently (Fiddes et al., 2010). 
Recent interest has been focused on the use of microfabrication technologies on 
PDMS material to produce surfaces that influence cell behavior including posts, 
holes, and channels. Although cell growth on microtextured surfaces with posts, 
holes and channels have been reported in the literature, the majority of the 
investigations have concentrated on cell response to patterned surfaces. Hsieh et al., 
2011 studied the alignment of dermal fibroblasts cultured on circular shape-patterned 
PDMS films with the diameters of  200, 300, 400, 600 and 800 µm (Hsieh et al., 
2011). Mata et al., 2002 studied the effects of smooth and microtextured PDMS 
surfaces on connective tissue progenitor cells (Mata et al., 2002). Mi et al., 2006 
cultured human Calu-2 epithelial cells on square, rectangular, stripe-like and mesh-
like structures (Mi et al., 2006). Kim et al., 2008 fabricated three different widths of 
a micro-pattern (1, 2, 4 µm) on PDMS (Kim et al., 2008).  
Biocompatibility is a pivotal factor that determines the adhesion between cells and 
scaffolds, and the ability of the newly developed biomaterial to serve in vivo. 
Different surface topographies of PDMS are used for biocompatibility comparisons. 
For example, Kim et al. 2008 studied neuronal differentiation of UCB-human MSCs 
on the modified surface of PDMS and flat PDMS. When they compared the UCB-
human MSCs on patterned PDMS and flat PDMS, they discovered that 1 μm width 
pattern showed an increase in neural-like cell differentiation of about two-folds 
compared to the flat PDMS (Kim et al., 2008). In another study, human bone 
marrow-derived connective tissue progenitor cells were cultured on smooth PDMS 
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surfaces and on PDMS post microtextures that were 6 μm high and 5, 10, 20 and 40 
μm in diameter. It was discovered that cells grown on 10 μm in diameter post 
microtextures showed three-folds increase in cell number than did the smooth PDMS 
(Mata et al., 2002). Kim et al., 2013 reported that the maximum number of human 
bone marrow-derived connective tissue progenitor cells was observed on the post 
microtextures with 20 μm height and 10 μm inter-space. It provided seven-folds 
increase relative to the smooth surface (Kim et al., 2013). To assess the behavior of 
ECs on structured PDMS surfaces, during our investigation, they were grown on flat 
PDMS or patterned PDMS with various surface geometries. It was demonstrated 
here for the first time that not only the design of a correct-diameter vessel-like 
tubular scaffold geometry is of great importance, but the structure of the surface 
where the cells will come to initial contact is also crucial for better EC adherence and 
viability. It was shown that cross-shaped patterned surface was most successful for 
supporting cell attachment and growth. This design exhibited higher level of 
roughness. However, the effect of the distance between geometrical figures on cell 
proliferation was evident when comparing five plus-shaped patterned surfaces. The 
results suggested that despite identical surface chemistry, P100 design had a 
significant effect on the biological performance of cells and suggested a potential 
role for microtextured surfaces of materials in vascular tissue engineering 
applications.   
Tissues with tubular structures including trachea, blood vessels and intestines have 
two important properties; i) their three-dimensional shapes; ii) having different types 
of cells at specific locations. Production of these layered tubes has some 
disadvantages. For example, tubular shape formation by manual rolling lasts three 
months and immobilizing cell sheets requires use of tools such as O-rings in order to 
provide tubular shape. Besides, controlling of cell location and orientation needs 
various efforts. To overcome these limitations, Yuan et al. (2012) developed a new 
method for the production of three-dimensional structures, named as SIRM. In this 
method, the fabrication was done by two elastic membranes together. The top 
membrane was named as cured PDMS and its aim was to produce stress. Unlike the 
top membrane, the bottom membrane was relaxed and semicured. After bonding of 
two layers to each other, they were baked for curing and adhesion. At the end, a 
SIRM was produced which could roll up on release because of its internal stress 
74 
(Yuan et al., 2012).  
In the study, before culturing cells with membranes produced according to the SIRM 
technique, the factors affecting the size and thickness of the wall were tested. As 
expected, the radius and tensile elongation were inversely proportional. While the 
radius decreased, tensile elongation increased because of ithe induction of larger 
stress by the larger elongation. As previously reported, the rolling time also was 
depended on the surface of the substrate. For example, smooth and clean surfaces 
such as glass provided a slower rolling. On the other hand, rough surfaces such as 
papers provided faster rolling (Yuan et al., 2012). 
Fabrication of vessel-like structures in 3D could be produced using various 
approaches. However, the method selected here had some advantages; a) distribution 
of the cells was easily achieved in 3D space, b) cell orientation could be easily 
controlled, c) the size of the tube could be arranged by changing the extent of 
elongation, d) rolling time was short without any extermal device. Therefore, this 
method was a powerful approach for the cultivation of the cells in 3D space.  
It is known that certain sterilization processes might create surface and pattern 
degradation with some scaffold materials (Kowalski and Morissey, 1996). The 
surfaces of PDMS were examined using light microscope to determine how the 
patterned features might be affected by sterilization. Therefore, cross-shaped PDMS 
surface was chosed for the experiment. Examination of the post-sterilization 
specimens from cross-shaped PDMS formulation did not reveal any discernable 
pattern degradation or surface distortion. 
In the study, the hydrophobicity properties of the various fabricated PDMS surfaces 
were characterized by the measurement of water. The results demonstrated that 
PDMS was a hydrophobic material, with a contact angle of about 110 degrees. 
The present study presented an initial and important step to develop a small-diameter 
vascular graft in vitro by using UCB-derived MSCs. These cells can be easily 
isolated and cryopreserved for many years. Their in vivo potential to be utilized in 
gene and cell therapies, especially in treatment of mesenchymal injuries/disorders 
requires further attention.  
MSCs are present in UCB. They have plastic adherence properties and differentiate 
successfully into ECs. From the literature survey, there is a need for a specific 
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marker for successful isolation of MSCs. An efficient way to expand the number of 
MSCs in UCB is needed, since low numbers are obtained from individual UCB 
samples; changing from person to person and time of the deliveries, affecting the 
reproducibility of the results. Moreover, the mechanism behind the differentiation 
and self-renewal properties of MSCs should be elucidated to provide an efficient 
work. 
In conclusion, the study presented a strategy to fabricate tubular scaffold structures 
similar to native vessel as well as efficient production of ECs from a novel source. 
Compared with previous methods for the fabrication of vessel-like structures, the 
advantage of the method was distribution of cells at a microscale resolution in 3D 
space and controlling of cell orientation inside the tube. The help of rolling ability of 
the sample can adjust the size and thickness of the tubes. The rolling time of the 
sample was short (within minutes) and the structure can be stable without any force. 
Thus, it offers an advantage for delivering of the cells inside the tube.  
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